BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott C, Meier W, Shapira-Frommer R, Safra T, Matei D, Macpherson E, Watkins C, Carmichael J, Matulonis U. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med 2012;366:1382-92. [PMID: 22452356 DOI: 10.1056/NEJMoa1105535] [Cited by in Crossref: 1069] [Cited by in F6Publishing: 496] [Article Influence: 118.8] [Reference Citation Analysis]
Number Citing Articles
1 Mauri G, Sartore-Bianchi A, Russo AG, Marsoni S, Bardelli A, Siena S. Early-onset colorectal cancer in young individuals. Mol Oncol. 2019;13:109-131. [PMID: 30520562 DOI: 10.1002/1878-0261.12417] [Cited by in Crossref: 99] [Cited by in F6Publishing: 90] [Article Influence: 33.0] [Reference Citation Analysis]
2 Gromova M, Vaggelas A, Dallmann G, Seimetz D. Biomarkers: Opportunities and Challenges for Drug Development in the Current Regulatory Landscape. Biomark Insights 2020;15:1177271920974652. [PMID: 33343195 DOI: 10.1177/1177271920974652] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
3 Carruthers R, Chalmers AJ. The potential of PARP inhibitors in neuro-oncology. CNS Oncol 2012;1:85-97. [PMID: 25054302 DOI: 10.2217/cns.12.13] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
4 Tookman L, Krell J, Nkolobe B, Burley L, McNeish IA. Practical guidance for the management of side effects during rucaparib therapy in a multidisciplinary UK setting. Ther Adv Med Oncol 2020;12:1758835920921980. [PMID: 32523631 DOI: 10.1177/1758835920921980] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Mabuchi S, Sugiyama T, Kimura T. Clear cell carcinoma of the ovary: molecular insights and future therapeutic perspectives. J Gynecol Oncol. 2016;27:e31. [PMID: 27029752 DOI: 10.3802/jgo.2016.27.e31] [Cited by in Crossref: 64] [Cited by in F6Publishing: 53] [Article Influence: 12.8] [Reference Citation Analysis]
6 Suh DH, Kim JW, Kim K, Kim HJ, Lee KH. Major clinical research advances in gynecologic cancer in 2012. J Gynecol Oncol 2013;24:66-82. [PMID: 23346316 DOI: 10.3802/jgo.2013.24.1.66] [Cited by in Crossref: 30] [Cited by in F6Publishing: 24] [Article Influence: 3.8] [Reference Citation Analysis]
7 Kim JW, Min A, Im SA, Jang H, Kim YJ, Kim HJ, Lee KH, Kim TY, Lee KW, Oh DY, Kim JH, Bang YJ. TDP1 and TOP1 Modulation in Olaparib-Resistant Cancer Determines the Efficacy of Subsequent Chemotherapy. Cancers (Basel) 2020;12:E334. [PMID: 32028591 DOI: 10.3390/cancers12020334] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
8 Gee ME, Faraahi Z, McCormick A, Edmondson RJ. DNA damage repair in ovarian cancer: unlocking the heterogeneity. J Ovarian Res 2018;11:50. [PMID: 29925418 DOI: 10.1186/s13048-018-0424-x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 6.3] [Reference Citation Analysis]
9 Markman M. Poly (ADP-ribose) polymerase inhibitors in the management of ovarian cancer. Womens Health (Lond) 2018;14:1745505717750694. [PMID: 29313444 DOI: 10.1177/1745505717750694] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
10 Chung WM, Chen L, Chang WC, Su SY, Hung YC, Ma WL. Androgen/Androgen Receptor Signaling in Ovarian Cancer: Molecular Regulation and Therapeutic Potentials. Int J Mol Sci 2021;22:7748. [PMID: 34299364 DOI: 10.3390/ijms22147748] [Reference Citation Analysis]
11 Julka PK, Verma A, Gupta K. Personalized Treatment Approach to Metastatic Castration-Resistant Prostate Cancer with BRCA2 and PTEN Mutations: A Case Report. Case Rep Oncol 2020;13:55-61. [PMID: 32110220 DOI: 10.1159/000505182] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
12 Petersen S, Wilson AJ, Hirst J, Roby KF, Fadare O, Crispens MA, Beeghly-Fadiel A, Khabele D. CCNE1 and BRD4 co-amplification in high-grade serous ovarian cancer is associated with poor clinical outcomes. Gynecol Oncol 2020;157:405-10. [PMID: 32044108 DOI: 10.1016/j.ygyno.2020.01.038] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 9.0] [Reference Citation Analysis]
13 Zheng S, Fu J, Vegesna R, Mao Y, Heathcock LE, Torres-Garcia W, Ezhilarasan R, Wang S, McKenna A, Chin L, Brennan CW, Yung WK, Weinstein JN, Aldape KD, Sulman EP, Chen K, Koul D, Verhaak RG. A survey of intragenic breakpoints in glioblastoma identifies a distinct subset associated with poor survival. Genes Dev 2013;27:1462-72. [PMID: 23796897 DOI: 10.1101/gad.213686.113] [Cited by in Crossref: 51] [Cited by in F6Publishing: 41] [Article Influence: 6.4] [Reference Citation Analysis]
14 Sonnenblick A, de Azambuja E, Azim HA Jr, Piccart M. An update on PARP inhibitors--moving to the adjuvant setting. Nat Rev Clin Oncol 2015;12:27-41. [PMID: 25286972 DOI: 10.1038/nrclinonc.2014.163] [Cited by in Crossref: 234] [Cited by in F6Publishing: 198] [Article Influence: 33.4] [Reference Citation Analysis]
15 Berlin J, Ramanathan RK, Strickler JH, Subramaniam DS, Marshall J, Kang YK, Hetman R, Dudley MW, Zeng J, Nickner C, Xiong H, Komarnitsky P, Shepherd SP, Hurwitz H, Lenz HJ. A phase 1 dose-escalation study of veliparib with bimonthly FOLFIRI in patients with advanced solid tumours. Br J Cancer. 2018;118:938-946. [PMID: 29527010 DOI: 10.1038/s41416-018-0003-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
16 Banerjee S, Gore M. Recent advances in systemic treatments for ovarian cancer. Cancer Imaging 2012;12:305-9. [PMID: 23022887 DOI: 10.1102/1470-7330.2012.9002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
17 Holen I, Speirs V, Morrissey B, Blyth K. In vivo models in breast cancer research: progress, challenges and future directions. Dis Model Mech 2017;10:359-71. [PMID: 28381598 DOI: 10.1242/dmm.028274] [Cited by in Crossref: 70] [Cited by in F6Publishing: 60] [Article Influence: 17.5] [Reference Citation Analysis]
18 Kieffer Y, Bonneau C, Popova T, Rouzier R, Stern MH, Mechta-Grigoriou F. Clinical Interest of Combining Transcriptomic and Genomic Signatures in High-Grade Serous Ovarian Cancer. Front Genet 2020;11:219. [PMID: 32256521 DOI: 10.3389/fgene.2020.00219] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
19 Reinbolt RE, Hays JL. The Role of PARP Inhibitors in the Treatment of Gynecologic Malignancies. Front Oncol 2013;3:237. [PMID: 24098868 DOI: 10.3389/fonc.2013.00237] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 4.3] [Reference Citation Analysis]
20 Friedlander M, Gebski V, Gibbs E, Davies L, Bloomfield R, Hilpert F, Wenzel LB, Eek D, Rodrigues M, Clamp A, Penson RT, Provencher D, Korach J, Huzarski T, Vidal L, Salutari V, Scott C, Nicoletto MO, Tamura K, Espinoza D, Joly F, Pujade-Lauraine E. Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trial. Lancet Oncol 2018;19:1126-34. [PMID: 30026002 DOI: 10.1016/S1470-2045(18)30343-7] [Cited by in Crossref: 67] [Cited by in F6Publishing: 34] [Article Influence: 22.3] [Reference Citation Analysis]
21 Sahin IH, Lowery MA, Stadler ZK, Salo-Mullen E, Iacobuzio-Donahue CA, Kelsen DP, O'Reilly EM. Genomic instability in pancreatic adenocarcinoma: a new step towards precision medicine and novel therapeutic approaches. Expert Rev Gastroenterol Hepatol. 2016;10:893-905. [PMID: 26881472 DOI: 10.1586/17474124.2016.1153424] [Cited by in Crossref: 11] [Cited by in F6Publishing: 17] [Article Influence: 2.2] [Reference Citation Analysis]
22 Min A, Lee KH, Im SA. DNA Damage Repair Inhibitor for Breast Cancer Treatment. Adv Exp Med Biol 2021;1187:159-79. [PMID: 33983578 DOI: 10.1007/978-981-32-9620-6_8] [Reference Citation Analysis]
23 Wiedemeyer WR, Beach JA, Karlan BY. Reversing Platinum Resistance in High-Grade Serous Ovarian Carcinoma: Targeting BRCA and the Homologous Recombination System. Front Oncol 2014;4:34. [PMID: 24624361 DOI: 10.3389/fonc.2014.00034] [Cited by in Crossref: 42] [Cited by in F6Publishing: 45] [Article Influence: 6.0] [Reference Citation Analysis]
24 Zhao Q, Yang J, Li L, Cao D, Yu M, Shen K; BGI Group. Germline and somatic mutations in homologous recombination genes among Chinese ovarian cancer patients detected using next-generation sequencing. J Gynecol Oncol 2017;28:e39. [PMID: 28541631 DOI: 10.3802/jgo.2017.28.e39] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
25 Provenzano M, Rotundo S, Chiodini P, Gagliardi I, Michael A, Angotti E, Borrelli S, Serra R, Foti D, De Sarro G, Andreucci M. Contribution of Predictive and Prognostic Biomarkers to Clinical Research on Chronic Kidney Disease. Int J Mol Sci 2020;21:E5846. [PMID: 32823966 DOI: 10.3390/ijms21165846] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 9.0] [Reference Citation Analysis]
26 Chau V, Madan RA, Figg WD. Exploiting defects in homologous recombination repair for metastatic, castration-resistant prostate cancer. Cancer Biol Ther 2020;21:884-7. [PMID: 32844710 DOI: 10.1080/15384047.2020.1809913] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
27 Jiang X, Li X, Li W, Bai H, Zhang Z. PARP inhibitors in ovarian cancer: Sensitivity prediction and resistance mechanisms. J Cell Mol Med 2019;23:2303-13. [PMID: 30672100 DOI: 10.1111/jcmm.14133] [Cited by in Crossref: 40] [Cited by in F6Publishing: 33] [Article Influence: 20.0] [Reference Citation Analysis]
28 Mafficini A, Simbolo M, Parisi A, Rusev B, Luchini C, Cataldo I, Piazzola E, Sperandio N, Turri G, Franchi M. BRCA somatic and germline mutation detection in paraffin embedded ovarian cancers by next-generation sequencing. Oncotarget. 2016;7:1076-1083. [PMID: 26745875 DOI: 10.18632/oncotarget.6834] [Cited by in Crossref: 51] [Cited by in F6Publishing: 46] [Article Influence: 10.2] [Reference Citation Analysis]
29 Smith AD, Roda D, Yap TA. Strategies for modern biomarker and drug development in oncology. J Hematol Oncol 2014;7:70. [PMID: 25277503 DOI: 10.1186/s13045-014-0070-8] [Cited by in Crossref: 84] [Cited by in F6Publishing: 78] [Article Influence: 12.0] [Reference Citation Analysis]
30 Gonzalez BD, Manne SL, Stapleton J, Myers-Virtue S, Ozga M, Kissane D, Heckman C, Morgan M. Quality of life trajectories after diagnosis of gynecologic cancer: a theoretically based approach. Support Care Cancer 2017;25:589-98. [PMID: 27757706 DOI: 10.1007/s00520-016-3443-4] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 2.6] [Reference Citation Analysis]
31 Liu JF, Barry WT, Birrer M, Lee JM, Buckanovich RJ, Fleming GF, Rimel B, Buss MK, Nattam S, Hurteau J, Luo W, Quy P, Whalen C, Obermayer L, Lee H, Winer EP, Kohn EC, Ivy SP, Matulonis UA. Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study. Lancet Oncol 2014;15:1207-14. [PMID: 25218906 DOI: 10.1016/S1470-2045(14)70391-2] [Cited by in Crossref: 362] [Cited by in F6Publishing: 169] [Article Influence: 51.7] [Reference Citation Analysis]
32 Coleman RL, Sill MW, Bell-McGuinn K, Aghajanian C, Gray HJ, Tewari KS, Rubin SC, Rutherford TJ, Chan JK, Chen A, Swisher EM. A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol 2015;137:386-91. [PMID: 25818403 DOI: 10.1016/j.ygyno.2015.03.042] [Cited by in Crossref: 155] [Cited by in F6Publishing: 143] [Article Influence: 25.8] [Reference Citation Analysis]
33 Bartoletti M, Pelizzari G, Gerratana L, Bortot L, Lombardi D, Nicoloso M, Scalone S, Giorda G, Baldassarre G, Sorio R, Puglisi F. Bevacizumab or PARP-Inhibitors Maintenance Therapy for Platinum-Sensitive Recurrent Ovarian Cancer: A Network Meta-Analysis. Int J Mol Sci 2020;21:E3805. [PMID: 32471250 DOI: 10.3390/ijms21113805] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
34 Shen J, Zhao W, Ju Z, Wang L, Peng Y, Labrie M, Yap TA, Mills GB, Peng G. PARPi Triggers the STING-Dependent Immune Response and Enhances the Therapeutic Efficacy of Immune Checkpoint Blockade Independent of BRCAness. Cancer Res 2019;79:311-9. [PMID: 30482774 DOI: 10.1158/0008-5472.CAN-18-1003] [Cited by in Crossref: 162] [Cited by in F6Publishing: 91] [Article Influence: 54.0] [Reference Citation Analysis]
35 Caracciolo D, Riillo C, Di Martino MT, Tagliaferri P, Tassone P. Alternative Non-Homologous End-Joining: Error-Prone DNA Repair as Cancer's Achilles' Heel. Cancers (Basel) 2021;13:1392. [PMID: 33808562 DOI: 10.3390/cancers13061392] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
36 Michels J, Vitale I, Senovilla L, Enot DP, Garcia P, Lissa D, Olaussen KA, Brenner C, Soria JC, Castedo M, Kroemer G. Synergistic interaction between cisplatin and PARP inhibitors in non-small cell lung cancer. Cell Cycle 2013;12:877-83. [PMID: 23428903 DOI: 10.4161/cc.24034] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 4.5] [Reference Citation Analysis]
37 Liu J, Westin SN. Rational selection of biomarker driven therapies for gynecologic cancers: The more we know, the more we know we don't know. Gynecol Oncol 2016;141:65-71. [PMID: 27016231 DOI: 10.1016/j.ygyno.2016.01.003] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
38 Gibson SJ, Tewari KS, Monk BJ, Chase DM. Updates on drug discovery in ovarian cancer. Gynecol Oncol Res Pract 2014;1:3. [PMID: 27231556 DOI: 10.1186/2053-6844-1-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
39 Sapiezynski J, Taratula O, Rodriguez-Rodriguez L, Minko T. Precision targeted therapy of ovarian cancer. J Control Release 2016;243:250-68. [PMID: 27746277 DOI: 10.1016/j.jconrel.2016.10.014] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 7.0] [Reference Citation Analysis]
40 Nishikawa T, Matsumoto K, Tamura K, Yoshida H, Imai Y, Miyasaka A, Onoe T, Yamaguchi S, Shimizu C, Yonemori K, Shimoi T, Yunokawa M, Xiong H, Nuthalapati S, Hashiba H, Kiriyama T, Leahy T, Komarnitsky P, Fujiwara K. Phase 1 dose-escalation study of single-agent veliparib in Japanese patients with advanced solid tumors. Cancer Sci 2017;108:1834-42. [PMID: 28665051 DOI: 10.1111/cas.13307] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
41 Madariaga A, Bowering V, Ahrari S, Oza AM, Lheureux S. Manage wisely: poly (ADP-ribose) polymerase inhibitor (PARPi) treatment and adverse events. Int J Gynecol Cancer 2020;30:903-15. [PMID: 32276934 DOI: 10.1136/ijgc-2020-001288] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 8.0] [Reference Citation Analysis]
42 Tewari KS. Fifth annual workshop of cytoreductive surgery for advanced ovarian cancer and peritoneal surface malignancies. Gynecol Oncol Res Pract 2016;3:10. [PMID: 28685778 DOI: 10.1186/s40661-016-0031-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
43 Li J, Wang R, Kong Y, Broman MM, Carlock C, Chen L, Li Z, Farah E, Ratliff TL, Liu X. Targeting Plk1 to Enhance Efficacy of Olaparib in Castration-Resistant Prostate Cancer. Mol Cancer Ther 2017;16:469-79. [PMID: 28069876 DOI: 10.1158/1535-7163.MCT-16-0361] [Cited by in Crossref: 24] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
44 Fleury H, Communal L, Carmona E, Portelance L, Arcand SL, Rahimi K, Tonin PN, Provencher D, Mes-Masson AM. Novel high-grade serous epithelial ovarian cancer cell lines that reflect the molecular diversity of both the sporadic and hereditary disease. Genes Cancer 2015;6:378-98. [PMID: 26622941 DOI: 10.18632/genesandcancer.76] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.7] [Reference Citation Analysis]
45 Szigyarto CA, Spitali P. Biomarkers of Duchenne muscular dystrophy: current findings. Degener Neurol Neuromuscul Dis 2018;8:1-13. [PMID: 30050384 DOI: 10.2147/DNND.S121099] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
46 Kaltofen T, Preinfalk V, Schwertler S, Fraungruber P, Heidegger H, Vilsmaier T, Vattai A, Czogalla B, Mayr D, Mahner S, Jeschke U, Trillsch F. Potential of platinum-resensitization by Wnt signaling modulators as treatment approach for epithelial ovarian cancer. J Cancer Res Clin Oncol 2020;146:2559-74. [PMID: 32681294 DOI: 10.1007/s00432-020-03317-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
47 Amuzu S, Carmona E, Mes-Masson AM, Greenwood CMT, Tonin PN, Ragoussis J. Candidate Markers of Olaparib Response from Genomic Data Analyses of Human Cancer Cell Lines. Cancers (Basel) 2021;13:1296. [PMID: 33803939 DOI: 10.3390/cancers13061296] [Reference Citation Analysis]
48 Kurnit KC, Coleman RL, Westin SN. Using PARP Inhibitors in the Treatment of Patients With Ovarian Cancer. Curr Treat Options Oncol 2018;19:1. [PMID: 30535808 DOI: 10.1007/s11864-018-0572-7] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 9.3] [Reference Citation Analysis]
49 Labrie M, Kim TB, Ju Z, Lee S, Zhao W, Fang Y, Lu Y, Chen K, Ramirez P, Frumovitz M, Meyer L, Fleming ND, Sood AK, Coleman RL, Mills GB, Westin SN. Adaptive responses in a PARP inhibitor window of opportunity trial illustrate limited functional interlesional heterogeneity and potential combination therapy options. Oncotarget 2019;10:3533-46. [PMID: 31191824 DOI: 10.18632/oncotarget.26947] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 4.5] [Reference Citation Analysis]
50 Shen Y, Rehman FL, Feng Y, Boshuizen J, Bajrami I, Elliott R, Wang B, Lord CJ, Post LE, Ashworth A. BMN 673, a novel and highly potent PARP1/2 inhibitor for the treatment of human cancers with DNA repair deficiency. Clin Cancer Res. 2013;19:5003-5015. [PMID: 23881923 DOI: 10.1158/1078-0432.ccr-13-1391] [Cited by in Crossref: 281] [Cited by in F6Publishing: 157] [Article Influence: 35.1] [Reference Citation Analysis]
51 El-Deiry WS, Goldberg RM, Lenz HJ, Shields AF, Gibney GT, Tan AR, Brown J, Eisenberg B, Heath EI, Phuphanich S, Kim E, Brenner AJ, Marshall JL. The current state of molecular testing in the treatment of patients with solid tumors, 2019. CA Cancer J Clin 2019;69:305-43. [PMID: 31116423 DOI: 10.3322/caac.21560] [Cited by in Crossref: 47] [Cited by in F6Publishing: 52] [Article Influence: 23.5] [Reference Citation Analysis]
52 de Castro E Gloria H, Jesuíno Nogueira L, Bencke Grudzinski P, da Costa Ghignatti PV, Guecheva TN, Motta Leguisamo N, Saffi J. Olaparib-mediated enhancement of 5-fluorouracil cytotoxicity in mismatch repair deficient colorectal cancer cells. BMC Cancer 2021;21:448. [PMID: 33888065 DOI: 10.1186/s12885-021-08188-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
53 Parkes EE, Kennedy RD. Clinical Application of Poly(ADP-Ribose) Polymerase Inhibitors in High-Grade Serous Ovarian Cancer. Oncologist 2016;21:586-93. [PMID: 27022037 DOI: 10.1634/theoncologist.2015-0438] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
54 O'Sullivan Coyne G, Chen AP, Meehan R, Doroshow JH. PARP Inhibitors in Reproductive System Cancers: Current Use and Developments. Drugs 2017;77:113-30. [PMID: 28078645 DOI: 10.1007/s40265-016-0688-7] [Cited by in Crossref: 29] [Cited by in F6Publishing: 21] [Article Influence: 7.3] [Reference Citation Analysis]
55 Barbosa A, Pinto P, Peixoto A, Guerra J, Pinto C, Santos C, Pinheiro M, Escudeiro C, Bartosch C, Silva J, Teixeira MR. Gene Panel Tumor Testing in Ovarian Cancer Patients Significantly Increases the Yield of Clinically Actionable Germline Variants beyond BRCA1/BRCA2. Cancers (Basel) 2020;12:E2834. [PMID: 33008098 DOI: 10.3390/cancers12102834] [Reference Citation Analysis]
56 Kast K, Rhiem K. Familial breast cancer - targeted therapy in secondary and tertiary prevention. Breast Care (Basel) 2015;10:27-31. [PMID: 25960722 DOI: 10.1159/000380756] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
57 Engelberth SA, Hempel N, Bergkvist M. Development of nanoscale approaches for ovarian cancer therapeutics and diagnostics. Crit Rev Oncog 2014;19:281-315. [PMID: 25271436 DOI: 10.1615/critrevoncog.2014011455] [Cited by in Crossref: 26] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
58 Lorusso D, García-Donas J, Sehouli J, Joly F. Management of Adverse Events During Rucaparib Treatment for Relapsed Ovarian Cancer: A Review of Published Studies and Practical Guidance. Target Oncol 2020;15:391-406. [PMID: 32495160 DOI: 10.1007/s11523-020-00715-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
59 Exman P, Barroso-Sousa R, Tolaney SM. Evidence to date: talazoparib in the treatment of breast cancer. Onco Targets Ther 2019;12:5177-87. [PMID: 31303769 DOI: 10.2147/OTT.S184971] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
60 Brody JR, Yabar CS, Zarei M, Bender J, Matrisian LM, Rahib L, Heartwell C, Mason K, Yeo CJ, Peiper SC, Jiang W, Varieur K, Madhavan S, Petricoin E 3rd, Fortuna D, Curtis M, Wang ZX, Pishvaian MJ, Winter JM. Identification of a novel metabolic-related mutation (IDH1) in metastatic pancreatic cancer. Cancer Biol Ther 2018;19:249-53. [PMID: 27466707 DOI: 10.1080/15384047.2016.1210743] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 3.7] [Reference Citation Analysis]
61 Romeo M, Pardo JC, Martínez-Cardús A, Martínez-Balibrea E, Quiroga V, Martínez-Román S, Solé F, Margelí M, Mesía R. Translational Research Opportunities Regarding Homologous Recombination in Ovarian Cancer. Int J Mol Sci 2018;19:E3249. [PMID: 30347758 DOI: 10.3390/ijms19103249] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
62 Konecny GE, Kristeleit RS. PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directions. Br J Cancer 2016;115:1157-73. [PMID: 27736844 DOI: 10.1038/bjc.2016.311] [Cited by in Crossref: 113] [Cited by in F6Publishing: 97] [Article Influence: 22.6] [Reference Citation Analysis]
63 Ni J, Cheng X, Zhao Q, Dai Z, Xu X, Guo W, Gu H, Zhou R, Wang Y, Chen X. The efficacy and safety of niraparib for ovarian cancer: a single-center observational study from China. J Ovarian Res 2021;14:68. [PMID: 33993885 DOI: 10.1186/s13048-021-00803-2] [Reference Citation Analysis]
64 Itamochi H, Kigawa J. Clinical trials and future potential of targeted therapy for ovarian cancer. Int J Clin Oncol 2012;17:430-40. [PMID: 22926640 DOI: 10.1007/s10147-012-0459-8] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 2.9] [Reference Citation Analysis]
65 Karakasis K, Burnier JV, Bowering V, Oza AM, Lheureux S. Ovarian Cancer and BRCA1/2 Testing: Opportunities to Improve Clinical Care and Disease Prevention. Front Oncol 2016;6:119. [PMID: 27242959 DOI: 10.3389/fonc.2016.00119] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
66 Tate S, Nishikimi K, Matsuoka A, Otsuka S, Shozu M. Safety and Efficacy of Weekly Paclitaxel and Cisplatin Chemotherapy for Ovarian Cancer Patients with Hypersensitivity to Carboplatin. Cancers (Basel) 2021;13:640. [PMID: 33562736 DOI: 10.3390/cancers13040640] [Reference Citation Analysis]
67 Bates JP, Derakhshandeh R, Jones L, Webb TJ. Mechanisms of immune evasion in breast cancer. BMC Cancer 2018;18:556. [PMID: 29751789 DOI: 10.1186/s12885-018-4441-3] [Cited by in Crossref: 63] [Cited by in F6Publishing: 58] [Article Influence: 21.0] [Reference Citation Analysis]
68 Shoji T, Sato C, Tomabechi H, Takatori E, Kaido Y, Nagasawa T, Kagabu M, Baba T. Expectations and Challenges of First-Line Maintenance Therapy for Advanced Ovarian Cancer. Medicina (Kaunas) 2021;57:501. [PMID: 34063455 DOI: 10.3390/medicina57050501] [Reference Citation Analysis]
69 Liu G, Yang D, Rupaimoole R, Pecot CV, Sun Y, Mangala LS, Li X, Ji P, Cogdell D, Hu L, Wang Y, Rodriguez-Aguayo C, Lopez-Berestein G, Shmulevich I, De Cecco L, Chen K, Mezzanzanica D, Xue F, Sood AK, Zhang W. Augmentation of response to chemotherapy by microRNA-506 through regulation of RAD51 in serous ovarian cancers. J Natl Cancer Inst 2015;107:djv108. [PMID: 25995442 DOI: 10.1093/jnci/djv108] [Cited by in Crossref: 64] [Cited by in F6Publishing: 66] [Article Influence: 10.7] [Reference Citation Analysis]
70 Yu G, Wang W, Deng J, Dong S. LncRNA AWPPH promotes the proliferation, migration and invasion of ovarian carcinoma cells via activation of the Wnt/β‑catenin signaling pathway. Mol Med Rep 2019;19:3615-21. [PMID: 30896797 DOI: 10.3892/mmr.2019.10029] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
71 Iavazzo C, Fotiou A, Tsiatas M, Christopoulou A, Spiliotis J, Sugarbaker P. Survey on the current gynaecological approach of ovarian cancer patients: The utility of HIPEC. Pleura Peritoneum 2020;5:20190029. [PMID: 32821775 DOI: 10.1515/pp-2019-0029] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
72 Zhang ZZ, Liu YJ, Yin XL, Zhan P, Gu Y, Ni XZ. Loss of BRCA1 expression leads to worse survival in patients with gastric carcinoma. World J Gastroenterol. 2013;19:1968-1974. [PMID: 23569343 DOI: 10.3748/wjg.v19.i12.1968] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
73 Hou S, Du P, Wang P, Wang C, Liu P, Liu H. Significance of MNK1 in prognostic prediction and chemotherapy development of epithelial ovarian cancer. Clin Transl Oncol 2017;19:1107-16. [PMID: 28332091 DOI: 10.1007/s12094-017-1646-x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 26] [Article Influence: 4.3] [Reference Citation Analysis]
74 Mateo J, Cheng HH, Beltran H, Dolling D, Xu W, Pritchard CC, Mossop H, Rescigno P, Perez-Lopez R, Sailer V, Kolinsky M, Balasopoulou A, Bertan C, Nanus DM, Tagawa ST, Thorne H, Montgomery B, Carreira S, Sandhu S, Rubin MA, Nelson PS, de Bono JS. Clinical Outcome of Prostate Cancer Patients with Germline DNA Repair Mutations: Retrospective Analysis from an International Study. Eur Urol 2018;73:687-93. [PMID: 29429804 DOI: 10.1016/j.eururo.2018.01.010] [Cited by in Crossref: 65] [Cited by in F6Publishing: 55] [Article Influence: 21.7] [Reference Citation Analysis]
75 Cho A, Park JY, Lee SW, Kim DY, Suh DS, Kim JH, Kim YM, Kim YT. Real-world experience of olaparib as maintenance therapy in BRCA-mutated recurrent ovarian cancer. Arch Gynecol Obstet 2021;304:1055-63. [PMID: 33871703 DOI: 10.1007/s00404-021-06013-x] [Reference Citation Analysis]
76 Girolimetti G, Perrone AM, Santini D, Barbieri E, Guerra F, Ferrari S, Zamagni C, De Iaco P, Gasparre G, Turchetti D. BRCA-associated ovarian cancer: from molecular genetics to risk management. Biomed Res Int 2014;2014:787143. [PMID: 25136623 DOI: 10.1155/2014/787143] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 4.7] [Reference Citation Analysis]
77 Ohmoto A, Yachida S. Current status of poly(ADP-ribose) polymerase inhibitors and future directions. Onco Targets Ther 2017;10:5195-208. [PMID: 29138572 DOI: 10.2147/OTT.S139336] [Cited by in Crossref: 71] [Cited by in F6Publishing: 38] [Article Influence: 17.8] [Reference Citation Analysis]
78 Ukai M, Yokoi A, Yoshida K, Suzuki S, Shibata K, Kikkawa F, Nakatsura T, Kajiyama H. Extracellular miRNAs as Predictive Biomarkers for Glypican-3-Derived Peptide Vaccine Therapy Response in Ovarian Clear Cell Carcinoma. Cancers (Basel) 2021;13:550. [PMID: 33535558 DOI: 10.3390/cancers13030550] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
79 Lin PC, Yeh YM, Wu PY, Hsu KF, Chang JY, Shen MR. Germline susceptibility variants impact clinical outcome and therapeutic strategies for stage III colorectal cancer. Sci Rep 2019;9:3931. [PMID: 30850667 DOI: 10.1038/s41598-019-40571-0] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
80 Yamamoto KN, Hirota K, Takeda S, Haeno H. Evolution of pre-existing versus acquired resistance to platinum drugs and PARP inhibitors in BRCA-associated cancers. PLoS One 2014;9:e105724. [PMID: 25158060 DOI: 10.1371/journal.pone.0105724] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
81 Burgess M, Puhalla S. BRCA 1/2-Mutation Related and Sporadic Breast and Ovarian Cancers: More Alike than Different. Front Oncol 2014;4:19. [PMID: 24579064 DOI: 10.3389/fonc.2014.00019] [Cited by in Crossref: 15] [Cited by in F6Publishing: 20] [Article Influence: 2.1] [Reference Citation Analysis]
82 Kurian AW, Ward KC, Abrahamse P, Bondarenko I, Hamilton AS, Deapen D, Morrow M, Berek JS, Hofer TP, Katz SJ. Time Trends in Receipt of Germline Genetic Testing and Results for Women Diagnosed With Breast Cancer or Ovarian Cancer, 2012-2019. J Clin Oncol 2021;39:1631-40. [PMID: 33560870 DOI: 10.1200/JCO.20.02785] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
83 Wang Y, Cardenas H, Fang F, Condello S, Taverna P, Segar M, Liu Y, Nephew KP, Matei D. Epigenetic targeting of ovarian cancer stem cells. Cancer Res 2014;74:4922-36. [PMID: 25035395 DOI: 10.1158/0008-5472.CAN-14-1022] [Cited by in Crossref: 94] [Cited by in F6Publishing: 65] [Article Influence: 13.4] [Reference Citation Analysis]
84 Conrad LB, Lin KY, Nandu T, Gibson BA, Lea JS, Kraus WL. ADP-Ribosylation Levels and Patterns Correlate with Gene Expression and Clinical Outcomes in Ovarian Cancers. Mol Cancer Ther 2020;19:282-91. [PMID: 31594824 DOI: 10.1158/1535-7163.MCT-19-0569] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
85 Brandt S, Samartzis EP, Zimmermann AK, Fink D, Moch H, Noske A, Dedes KJ. Lack of MRE11-RAD50-NBS1 (MRN) complex detection occurs frequently in low-grade epithelial ovarian cancer. BMC Cancer 2017;17:44. [PMID: 28073364 DOI: 10.1186/s12885-016-3026-2] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 4.8] [Reference Citation Analysis]
86 Athie A, Arce-Gallego S, Gonzalez M, Morales-Barrera R, Suarez C, Casals Galobart T, Hernandez Viedma G, Carles J, Mateo J. Targeting DNA Repair Defects for Precision Medicine in Prostate Cancer. Curr Oncol Rep 2019;21:42. [PMID: 30919167 DOI: 10.1007/s11912-019-0790-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
87 Bitler BG, Watson ZL, Wheeler LJ, Behbakht K. PARP inhibitors: Clinical utility and possibilities of overcoming resistance. Gynecol Oncol 2017;147:695-704. [PMID: 29037806 DOI: 10.1016/j.ygyno.2017.10.003] [Cited by in Crossref: 115] [Cited by in F6Publishing: 96] [Article Influence: 28.8] [Reference Citation Analysis]
88 Caffo O, Veccia A, Kinspergher S, Rizzo M, Maines F. Aberrations of DNA Repair Pathways in Prostate Cancer: Future Implications for Clinical Practice? Front Cell Dev Biol 2018;6:71. [PMID: 30234108 DOI: 10.3389/fcell.2018.00071] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 2.3] [Reference Citation Analysis]
89 Shipman H, Flynn S, MacDonald-Smith CF, Brenton J, Crawford R, Tischkowitz M, Hulbert-Williams NJ; GTEOC Study Group. Universal BRCA1/BRCA2 Testing for Ovarian Cancer Patients is Welcomed, but with Care: How Women and Staff Contextualize Experiences of Expanded Access. J Genet Couns 2017;26:1280-91. [PMID: 28540621 DOI: 10.1007/s10897-017-0108-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
90 Ivy SP, de Bono J, Kohn EC. The 'Pushmi-Pullyu' of DNA REPAIR: Clinical Synthetic Lethality. Trends Cancer 2016;2:646-56. [PMID: 28741503 DOI: 10.1016/j.trecan.2016.10.014] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
91 Decker JT, Hobson EC, Zhang Y, Shin S, Thomas AL, Jeruss JS, Arnold KB, Shea LD. Systems analysis of dynamic transcription factor activity identifies targets for treatment in Olaparib resistant cancer cells. Biotechnol Bioeng 2017;114:2085-95. [PMID: 28322442 DOI: 10.1002/bit.26293] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
92 Ma J, Deng H, Li J, Hu S, Yang Y, Liu S, Han X. Efficacy and safety of olaparib maintenance therapy in platinum-sensitive ovarian cancer patients with BRCA mutations: a meta-analysis on randomized controlled trials. Cancer Manag Res 2019;11:3061-78. [PMID: 31114351 DOI: 10.2147/CMAR.S191107] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
93 Shao F, Liu J, Duan Y, Li L, Liu L, Zhang C, He S. Efficacy and safety of PARP inhibitors as the maintenance therapy in ovarian cancer: a meta-analysis of nine randomized controlled trials. Biosci Rep 2020;40:BSR20192226. [PMID: 32096544 DOI: 10.1042/BSR20192226] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
94 Frey MK, Pothuri B. Homologous recombination deficiency (HRD) testing in ovarian cancer clinical practice: a review of the literature. Gynecol Oncol Res Pract 2017;4:4. [PMID: 28250960 DOI: 10.1186/s40661-017-0039-8] [Cited by in Crossref: 44] [Cited by in F6Publishing: 35] [Article Influence: 11.0] [Reference Citation Analysis]
95 Nakanishi K, Yamada T, Ishikawa G, Suzuki S. Beyond BRCA Status: Clinical Biomarkers May Predict Therapeutic Effects of Olaparib in Platinum-Sensitive Ovarian Cancer Recurrence. Front Oncol 2021;11:697952. [PMID: 34395265 DOI: 10.3389/fonc.2021.697952] [Reference Citation Analysis]
96 Michel LS, Dyroff S, Brooks FJ, Spayd KJ, Lim S, Engle JT, Phillips S, Tan B, Wang-Gillam A, Bognar C, Chu W, Zhou D, Mach RH, Laforest R, Chen DL. PET of Poly (ADP-Ribose) Polymerase Activity in Cancer: Preclinical Assessment and First In-Human Studies. Radiology 2017;282:453-63. [PMID: 27841728 DOI: 10.1148/radiol.2016161929] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 6.2] [Reference Citation Analysis]
97 Shao F, Duan Y, Zhao Y, Li Y, Liu J, Zhang C, He S. PARP inhibitors in breast and ovarian cancer with BRCA mutations: a meta-analysis of survival. Aging (Albany NY) 2021;13:8975-88. [PMID: 33705352 DOI: 10.18632/aging.202724] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
98 Chung WM, Ho YP, Chang WC, Dai YC, Chen L, Hung YC, Ma WL. Increase Paclitaxel Sensitivity to Better Suppress Serous Epithelial Ovarian Cancer via Ablating Androgen Receptor/Aryl Hydrocarbon Receptor-ABCG2 Axis. Cancers (Basel) 2019;11:E463. [PMID: 30986993 DOI: 10.3390/cancers11040463] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 5.5] [Reference Citation Analysis]
99 Shi T, Jiang R, Yu J, Yang H, Tu D, Dai Z, Shen Y, Zhang Y, Cheng X, Jia H, Tu R, Wang H, Tang J, Luan Y, Cai S, Zang R; SGOG-OV/AICE Investigators. Addition of intraperitoneal cisplatin and etoposide to first-line chemotherapy for advanced ovarian cancer: a randomised, phase 2 trial. Br J Cancer 2018;119:12-8. [PMID: 29899395 DOI: 10.1038/s41416-018-0036-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
100 Wiggans AJ, Cass GK, Bryant A, Lawrie TA, Morrison J. Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer. Cochrane Database Syst Rev 2015;:CD007929. [PMID: 25991068 DOI: 10.1002/14651858.CD007929.pub3] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 2.7] [Reference Citation Analysis]
101 Song Z, Tu X, Zhou Q, Huang J, Chen Y, Liu J, Lee S, Kim W, Nowsheen S, Luo K, Yuan J, Lou Z. A novel UCHL3 inhibitor, perifosine, enhances PARP inhibitor cytotoxicity through inhibition of homologous recombination-mediated DNA double strand break repair. Cell Death Dis 2019;10:398. [PMID: 31113933 DOI: 10.1038/s41419-019-1628-8] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
102 Pearson SJ, Elswood J, Barhoumi R, Ming-Whitfield B, Rijnkels M, Porter WW. Loss of SIM2s inhibits RAD51 binding and leads to unresolved replication stress. Breast Cancer Res 2019;21:125. [PMID: 31775907 DOI: 10.1186/s13058-019-1207-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
103 Stemmer A, Shafran I, Stemmer SM, Tsoref D. Comparison of Poly (ADP-ribose) Polymerase Inhibitors (PARPis) as Maintenance Therapy for Platinum-Sensitive Ovarian Cancer: Systematic Review and Network Meta-Analysis. Cancers (Basel) 2020;12:E3026. [PMID: 33081005 DOI: 10.3390/cancers12103026] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
104 Joshi PM, Sutor SL, Huntoon CJ, Karnitz LM. Ovarian cancer-associated mutations disable catalytic activity of CDK12, a kinase that promotes homologous recombination repair and resistance to cisplatin and poly(ADP-ribose) polymerase inhibitors. J Biol Chem 2014;289:9247-53. [PMID: 24554720 DOI: 10.1074/jbc.M114.551143] [Cited by in Crossref: 111] [Cited by in F6Publishing: 71] [Article Influence: 15.9] [Reference Citation Analysis]
105 Solimando DA Jr, Waddell JA. Nivolumab and Olaparib. Hosp Pharm 2015;50:356-66. [PMID: 26405320 DOI: 10.1310/hpj5005-356] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
106 Jiang Y, Zhao J, Zhang L, Tian S, Yang T, Wang L, Zhao M, Yang Q, Wang Y, Yang X. Evaluation of the Efficacy and Safety of PARP Inhibitors in Advanced-Stage Epithelial Ovarian Cancer. Front Oncol 2020;10:954. [PMID: 32719741 DOI: 10.3389/fonc.2020.00954] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
107 Milletti G, Strocchio L, Pagliara D, Girardi K, Carta R, Mastronuzzi A, Locatelli F, Nazio F. Canonical and Noncanonical Roles of Fanconi Anemia Proteins: Implications in Cancer Predisposition. Cancers (Basel) 2020;12:E2684. [PMID: 32962238 DOI: 10.3390/cancers12092684] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 11.0] [Reference Citation Analysis]
108 Previs RA, Sood AK, Mills GB, Westin SN. The rise of genomic profiling in ovarian cancer. Expert Rev Mol Diagn 2016;16:1337-51. [PMID: 27828713 DOI: 10.1080/14737159.2016.1259069] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
109 Matulonis UA, Sood AK, Fallowfield L, Howitt BE, Sehouli J, Karlan BY. Ovarian cancer. Nat Rev Dis Primers 2016;2:16061. [PMID: 27558151 DOI: 10.1038/nrdp.2016.61] [Cited by in Crossref: 300] [Cited by in F6Publishing: 248] [Article Influence: 60.0] [Reference Citation Analysis]
110 Gadducci A, Guarneri V, Peccatori FA, Ronzino G, Scandurra G, Zamagni C, Zola P, Salutari V. Current strategies for the targeted treatment of high-grade serous epithelial ovarian cancer and relevance of BRCA mutational status. J Ovarian Res 2019;12:9. [PMID: 30691488 DOI: 10.1186/s13048-019-0484-6] [Cited by in Crossref: 32] [Cited by in F6Publishing: 24] [Article Influence: 16.0] [Reference Citation Analysis]
111 Liang MI, Huh WK. Financial toxicity - An overlooked side effect. Gynecol Oncol 2018;150:3-6. [PMID: 29778508 DOI: 10.1016/j.ygyno.2018.05.012] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
112 Drew Y, Kristeleit RS, Oaknin A, Ray-Coquard I, Haris NM, Swisher EM. Real-World Delivery of Rucaparib to Patients with Ovarian Cancer: Recommendations Based on an Integrated Safety Analysis of ARIEL2 and Study 10. Oncologist 2020;25:e109-19. [PMID: 31575788 DOI: 10.1634/theoncologist.2019-0229] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
113 McMullen M, Karakasis K, Loembe B, Dean E, Parr G, Oza AM. DUETTE: a phase II randomized, multicenter study to investigate the efficacy and tolerability of a second maintenance treatment in patients with platinum-sensitive relapsed epithelial ovarian cancer, who have previously received poly(ADP-ribose) polymerase (PARP) inhibitor maintenance treatment. Int J Gynecol Cancer 2020;30:1824-8. [PMID: 32878963 DOI: 10.1136/ijgc-2020-001694] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
114 Ledermann JA, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, Colombo N, Weberpals JI, Clamp AR, Scambia G, Leary A, Holloway RW, Gancedo MA, Fong PC, Goh JC, O'Malley DM, Armstrong DK, Banerjee S, García-Donas J, Swisher EM, Cameron T, Maloney L, Goble S, Coleman RL. Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial. Lancet Oncol 2020;21:710-22. [PMID: 32359490 DOI: 10.1016/S1470-2045(20)30061-9] [Cited by in Crossref: 14] [Cited by in F6Publishing: 3] [Article Influence: 14.0] [Reference Citation Analysis]
115 Luvero D, Milani A, Ledermann JA. Treatment options in recurrent ovarian cancer: latest evidence and clinical potential. Ther Adv Med Oncol 2014;6:229-39. [PMID: 25342990 DOI: 10.1177/1758834014544121] [Cited by in Crossref: 120] [Cited by in F6Publishing: 103] [Article Influence: 17.1] [Reference Citation Analysis]
116 Moore KN, Monk BJ. Patient Counseling and Management of Symptoms During Olaparib Therapy for Recurrent Ovarian Cancer. Oncologist 2016;21:954-63. [PMID: 27256873 DOI: 10.1634/theoncologist.2015-0268] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 3.6] [Reference Citation Analysis]
117 Hollis RL, Churchman M, Michie CO, Rye T, Knight L, McCavigan A, Perren T, Williams ARW, McCluggage WG, Kaplan RS, Jayson GC, Oza A, Harkin DP, Herrington CS, Kennedy R, Gourley C. High EMSY expression defines a BRCA-like subgroup of high-grade serous ovarian carcinoma with prolonged survival and hypersensitivity to platinum. Cancer 2019;125:2772-81. [PMID: 31154673 DOI: 10.1002/cncr.32079] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
118 Liu G, Yang D, Sun Y, Shmulevich I, Xue F, Sood AK, Zhang W. Differing clinical impact of BRCA1 and BRCA2 mutations in serous ovarian cancer. Pharmacogenomics 2012;13:1523-35. [PMID: 23057551 DOI: 10.2217/pgs.12.137] [Cited by in Crossref: 37] [Cited by in F6Publishing: 29] [Article Influence: 4.6] [Reference Citation Analysis]
119 Ito S, Murphy CG, Doubrovina E, Jasin M, Moynahan ME. PARP Inhibitors in Clinical Use Induce Genomic Instability in Normal Human Cells. PLoS One 2016;11:e0159341. [PMID: 27428646 DOI: 10.1371/journal.pone.0159341] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 5.4] [Reference Citation Analysis]
120 Ledermann JA, Pujade-Lauraine E. Olaparib as maintenance treatment for patients with platinum-sensitive relapsed ovarian cancer. Ther Adv Med Oncol 2019;11:1758835919849753. [PMID: 31205507 DOI: 10.1177/1758835919849753] [Cited by in Crossref: 35] [Cited by in F6Publishing: 28] [Article Influence: 17.5] [Reference Citation Analysis]
121 Prieske K, Prieske S, Joosse SA, Trillsch F, Grimm D, Burandt E, Mahner S, Schmalfeldt B, Milde-Langosch K, Oliveira-Ferrer L, Woelber L. Loss of BRCA1 promotor hypermethylation in recurrent high-grade ovarian cancer. Oncotarget 2017;8:83063-74. [PMID: 29137324 DOI: 10.18632/oncotarget.20945] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
122 Cadoo KA, Grisham RN, O'Cearbhaill RE, Boucicaut NN, Henson M, Iasonos A, Zhou Q, Sarasohn DM, Gallagher J, Kravetz S, Zamarin D, Makker V, Sabbatini PJ, Tew WP, Aghajanian C, Konner JA. A phase 1 dose-escalation study of intraperitoneal cisplatin, intravenous/intraperitoneal paclitaxel, bevacizumab, and olaparib for newly diagnosed ovarian cancer. Gynecol Oncol 2020;157:214-21. [PMID: 31959492 DOI: 10.1016/j.ygyno.2020.01.018] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
123 Burney IA, Lakhtakia R. Precision Medicine: Where have we reached and where are we headed? Sultan Qaboos Univ Med J 2017;17:e255-8. [PMID: 29062546 DOI: 10.18295/squmj.2017.17.03.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
124 Yonemori K, Tamura K, Kodaira M, Fujikawa K, Sagawa T, Esaki T, Shirakawa T, Hirai F, Yokoi Y, Kawata T, Hatano B, Takahashi Y. Safety and tolerability of the olaparib tablet formulation in Japanese patients with advanced solid tumours. Cancer Chemother Pharmacol 2016;78:525-31. [PMID: 27422301 DOI: 10.1007/s00280-016-3106-7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
125 McGee J, Peart TM, Foley N, Bertrand M, Prefontaine M, Sugimoto A, Ettler H, Welch S, Panabaker K. Direct Genetics Referral Pathway for High-Grade Serous Ovarian Cancer Patients: The "Opt-Out" Process. J Oncol 2019;2019:6029097. [PMID: 31061661 DOI: 10.1155/2019/6029097] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
126 Harrison RF, Fu S, Sun CC, Zhao H, Lu KH, Giordano SH, Meyer LA. Patient cost sharing during poly(adenosine diphosphate-ribose) polymerase inhibitor treatment in ovarian cancer. Am J Obstet Gynecol 2021;225:68.e1-68.e11. [PMID: 33549538 DOI: 10.1016/j.ajog.2021.01.029] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
127 Gomez MK, Illuzzi G, Colomer C, Churchman M, Hollis RL, O'Connor MJ, Gourley C, Leo E, Melton DW. Identifying and Overcoming Mechanisms of PARP Inhibitor Resistance in Homologous Recombination Repair-Deficient and Repair-Proficient High Grade Serous Ovarian Cancer Cells. Cancers (Basel) 2020;12:E1503. [PMID: 32526907 DOI: 10.3390/cancers12061503] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
128 Pothuri B, Alvarez Secord A, Armstrong DK, Chan J, Fader AN, Huh W, Kesterson J, Liu JF, Moore K, Westin SN, Naumann RW. Anti-cancer therapy and clinical trial considerations for gynecologic oncology patients during the COVID-19 pandemic crisis. Gynecol Oncol 2020;158:16-24. [PMID: 32386911 DOI: 10.1016/j.ygyno.2020.04.694] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 25.0] [Reference Citation Analysis]
129 Ledermann JA, El-Khouly F. PARP inhibitors in ovarian cancer: Clinical evidence for informed treatment decisions. Br J Cancer 2015;113 Suppl 1:S10-6. [PMID: 26669450 DOI: 10.1038/bjc.2015.395] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 4.2] [Reference Citation Analysis]
130 Mesquita KA, Ali R, Doherty R, Toss MS, Miligy I, Alblihy A, Dorjsuren D, Simeonov A, Jadhav A, Wilson DM 3rd, Hickson I, Tatum NJ, Rakha EA, Madhusudan S. FEN1 Blockade for Platinum Chemo-Sensitization and Synthetic Lethality in Epithelial Ovarian Cancers. Cancers (Basel) 2021;13:1866. [PMID: 33919707 DOI: 10.3390/cancers13081866] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
131 Fleury H, Carmona E, Morin VG, Meunier L, Masson JY, Tonin PN, Provencher D, Mes-Masson AM. Cumulative defects in DNA repair pathways drive the PARP inhibitor response in high-grade serous epithelial ovarian cancer cell lines. Oncotarget 2017;8:40152-68. [PMID: 27374179 DOI: 10.18632/oncotarget.10308] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
132 Isaacsson Velho P, Silberstein JL, Markowski MC, Luo J, Lotan TL, Isaacs WB, Antonarakis ES. Intraductal/ductal histology and lymphovascular invasion are associated with germline DNA-repair gene mutations in prostate cancer. Prostate 2018;78:401-7. [PMID: 29368341 DOI: 10.1002/pros.23484] [Cited by in Crossref: 54] [Cited by in F6Publishing: 48] [Article Influence: 18.0] [Reference Citation Analysis]
133 Song H, Cicek MS, Dicks E, Harrington P, Ramus SJ, Cunningham JM, Fridley BL, Tyrer JP, Alsop J, Jimenez-Linan M, Gayther SA, Goode EL, Pharoah PD. The contribution of deleterious germline mutations in BRCA1, BRCA2 and the mismatch repair genes to ovarian cancer in the population. Hum Mol Genet. 2014;23:4703-4709. [PMID: 24728189 DOI: 10.1093/hmg/ddu172] [Cited by in Crossref: 79] [Cited by in F6Publishing: 60] [Article Influence: 11.3] [Reference Citation Analysis]
134 Lee JM, Ledermann JA, Kohn EC. PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies. Ann Oncol. 2014;25:32-40. [PMID: 24225019 DOI: 10.1093/annonc/mdt384] [Cited by in Crossref: 206] [Cited by in F6Publishing: 174] [Article Influence: 25.8] [Reference Citation Analysis]
135 Jenner ZB, Sood AK, Coleman RL. Evaluation of rucaparib and companion diagnostics in the PARP inhibitor landscape for recurrent ovarian cancer therapy. Future Oncol 2016;12:1439-56. [PMID: 27087632 DOI: 10.2217/fon-2016-0002] [Cited by in Crossref: 46] [Cited by in F6Publishing: 41] [Article Influence: 9.2] [Reference Citation Analysis]
136 Dietz S, Sültmann H, Du Y, Reisinger E, Riediger AL, Volckmar AL, Stenzinger A, Schlesner M, Jäger D, Hohenfellner M, Duensing S, Grüllich C, Pahernik S. Patient-specific molecular alterations are associated with metastatic clear cell renal cell cancer progressing under tyrosine kinase inhibitor therapy. Oncotarget 2017;8:74049-57. [PMID: 29088767 DOI: 10.18632/oncotarget.18200] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
137 Plummer R, Stephens P, Aissat-Daudigny L, Cambois A, Moachon G, Brown PD, Campone M. Phase 1 dose-escalation study of the PARP inhibitor CEP-9722 as monotherapy or in combination with temozolomide in patients with solid tumors. Cancer Chemother Pharmacol 2014;74:257-65. [PMID: 24880570 DOI: 10.1007/s00280-014-2486-9] [Cited by in Crossref: 23] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
138 Dobbelstein M, Sørensen CS. Exploiting replicative stress to treat cancer. Nat Rev Drug Discov 2015;14:405-23. [PMID: 25953507 DOI: 10.1038/nrd4553] [Cited by in Crossref: 177] [Cited by in F6Publishing: 143] [Article Influence: 29.5] [Reference Citation Analysis]
139 Cheng H, Zhang Z, Borczuk A, Powell CA, Balajee AS, Lieberman HB, Halmos B. PARP inhibition selectively increases sensitivity to cisplatin in ERCC1-low non-small cell lung cancer cells. Carcinogenesis 2013;34:739-49. [PMID: 23275151 DOI: 10.1093/carcin/bgs393] [Cited by in Crossref: 60] [Cited by in F6Publishing: 55] [Article Influence: 6.7] [Reference Citation Analysis]
140 Antolin AA, Ameratunga M, Banerji U, Clarke PA, Workman P, Al-Lazikani B. The kinase polypharmacology landscape of clinical PARP inhibitors. Sci Rep 2020;10:2585. [PMID: 32066817 DOI: 10.1038/s41598-020-59074-4] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 21.0] [Reference Citation Analysis]
141 Mateo J, Lord CJ, Serra V, Tutt A, Balmaña J, Castroviejo-Bermejo M, Cruz C, Oaknin A, Kaye SB, de Bono JS. A decade of clinical development of PARP inhibitors in perspective. Ann Oncol 2019;30:1437-47. [PMID: 31218365 DOI: 10.1093/annonc/mdz192] [Cited by in Crossref: 135] [Cited by in F6Publishing: 113] [Article Influence: 135.0] [Reference Citation Analysis]
142 Nakagomi H, Mochizuki H, Inoue M, Hirotsu Y, Amemiya K, Sakamoto I, Nakagomi S, Kubota T, Omata M. Combined annotation-dependent depletion score for BRCA1/2 variants in patients with breast and/or ovarian cancer. Cancer Sci 2018;109:453-61. [PMID: 29215753 DOI: 10.1111/cas.13464] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
143 Moiseyenko VM, Chubenko VA, Moiseyenko FV, Zagorskaya LA, Zaytseva YA, Gesha NE, Zykov EN, Ni VI, Preobrazhenskaya EV, Sokolenko AP, Imyanitov EN. "Lazarus Response" to Olaparib in a Virtually Chemonaive Breast Cancer Patient Carrying Gross BRCA2 Gene Deletion. Cureus. 2018;10:e2150. [PMID: 29651367 DOI: 10.7759/cureus.2150] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
144 Hendriks IA, Larsen SC, Nielsen ML. An Advanced Strategy for Comprehensive Profiling of ADP-ribosylation Sites Using Mass Spectrometry-based Proteomics. Mol Cell Proteomics 2019;18:1010-26. [PMID: 30798302 DOI: 10.1074/mcp.TIR119.001315] [Cited by in Crossref: 42] [Cited by in F6Publishing: 22] [Article Influence: 21.0] [Reference Citation Analysis]
145 Turina CB, Coleman DJ, Thomas GV, Fung AW, Alumkal JJ. Molecular Testing Identifies Determinants of Exceptional Response and Guides Precision Therapy in a Patient with Lethal, Treatment-emergent Neuroendocrine Prostate Cancer. Cureus 2019;11:e5197. [PMID: 31565603 DOI: 10.7759/cureus.5197] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
146 Biau J, Chautard E, Verrelle P, Dutreix M. Altering DNA Repair to Improve Radiation Therapy: Specific and Multiple Pathway Targeting. Front Oncol 2019;9:1009. [PMID: 31649878 DOI: 10.3389/fonc.2019.01009] [Cited by in Crossref: 34] [Cited by in F6Publishing: 27] [Article Influence: 17.0] [Reference Citation Analysis]
147 Hatano Y, Hatano K, Tamada M, Morishige KI, Tomita H, Yanai H, Hara A. A Comprehensive Review of Ovarian Serous Carcinoma. Adv Anat Pathol 2019;26:329-39. [PMID: 31368906 DOI: 10.1097/PAP.0000000000000243] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 11.0] [Reference Citation Analysis]
148 Kohn EC, Ivy SP. Confronting the Care Delivery Challenges Arising from Precision Medicine. Front Oncol 2016;6:106. [PMID: 27200294 DOI: 10.3389/fonc.2016.00106] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
149 Kondrashova O, Topp M, Nesic K, Lieschke E, Ho GY, Harrell MI, Zapparoli GV, Hadley A, Holian R, Boehm E, Heong V, Sanij E, Pearson RB, Krais JJ, Johnson N, McNally O, Ananda S, Alsop K, Hutt KJ, Kaufmann SH, Lin KK, Harding TC, Traficante N, deFazio A, McNeish IA, Bowtell DD, Swisher EM, Dobrovic A, Wakefield MJ, Scott CL; Australian Ovarian Cancer Study (AOCS). Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma. Nat Commun 2018;9:3970. [PMID: 30266954 DOI: 10.1038/s41467-018-05564-z] [Cited by in Crossref: 83] [Cited by in F6Publishing: 69] [Article Influence: 27.7] [Reference Citation Analysis]
150 Valabrega G, Scotto G, Tuninetti V, Pani A, Scaglione F. Differences in PARP Inhibitors for the Treatment of Ovarian Cancer: Mechanisms of Action, Pharmacology, Safety, and Efficacy. Int J Mol Sci 2021;22:4203. [PMID: 33921561 DOI: 10.3390/ijms22084203] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
151 Touboul C, Vidal F, Pasquier J, Lis R, Rafii A. Role of mesenchymal cells in the natural history of ovarian cancer: a review. J Transl Med 2014;12:271. [PMID: 25303976 DOI: 10.1186/s12967-014-0271-5] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.6] [Reference Citation Analysis]
152 Bookman MA. Should studies of maintenance therapy be maintained in women with ovarian cancer? J Gynecol Oncol 2013;24:105-7. [PMID: 23653825 DOI: 10.3802/jgo.2013.24.2.105] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
153 Guo XX, Wu HL, Shi HY, Su L, Zhang X. The efficacy and safety of olaparib in the treatment of cancers: a meta-analysis of randomized controlled trials. Cancer Manag Res 2018;10:2553-62. [PMID: 30127642 DOI: 10.2147/CMAR.S169558] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
154 Barretina-Ginesta MP. DNA damaging agents in ovarian cancer. EJC Suppl 2020;15:67-72. [PMID: 33240444 DOI: 10.1016/j.ejcsup.2020.06.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
155 Principe DR, Narbutis M, Koch R, Rana A. Frequency and prognostic value of mutations associated with the homologous recombination DNA repair pathway in a large pan cancer cohort. Sci Rep 2020;10:20223. [PMID: 33214570 DOI: 10.1038/s41598-020-76975-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
156 Gentles L, Goranov B, Matheson E, Herriott A, Kaufmann A, Hall S, Mukhopadhyay A, Drew Y, Curtin NJ, O'Donnell RL. Exploring the Frequency of Homologous Recombination DNA Repair Dysfunction in Multiple Cancer Types. Cancers (Basel) 2019;11:E354. [PMID: 30871186 DOI: 10.3390/cancers11030354] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 4.5] [Reference Citation Analysis]
157 Klotz DM, Wimberger P. Overcoming PARP inhibitor resistance in ovarian cancer: what are the most promising strategies? Arch Gynecol Obstet 2020;302:1087-102. [PMID: 32833070 DOI: 10.1007/s00404-020-05677-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
158 Makvandi M, Xu K, Lieberman BP, Anderson RC, Effron SS, Winters HD, Zeng C, McDonald ES, Pryma DA, Greenberg RA, Mach RH. A Radiotracer Strategy to Quantify PARP-1 Expression In Vivo Provides a Biomarker That Can Enable Patient Selection for PARP Inhibitor Therapy. Cancer Res 2016;76:4516-24. [PMID: 27261505 DOI: 10.1158/0008-5472.CAN-16-0416] [Cited by in Crossref: 50] [Cited by in F6Publishing: 35] [Article Influence: 10.0] [Reference Citation Analysis]
159 Li P, Zhen Y, Yu Y. Site-specific analysis of the Asp- and Glu-ADP-ribosylated proteome by quantitative mass spectrometry. Methods Enzymol 2019;626:301-21. [PMID: 31606080 DOI: 10.1016/bs.mie.2019.06.024] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
160 Shimomura A, Yonemori K, Yoshida M, Yoshida T, Yasojima H, Masuda N, Aogi K, Takahashi M, Naito Y, Shimizu S, Nakamura R, Hamada A, Michimae H, Hashimoto J, Yamamoto H, Kawachi A, Shimizu C, Fujiwara Y, Tamura K. Gene Alterations in Triple-Negative Breast Cancer Patients in a Phase I/II Study of Eribulin and Olaparib Combination Therapy. Transl Oncol 2019;12:1386-94. [PMID: 31382135 DOI: 10.1016/j.tranon.2019.07.013] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
161 Kaye SB. Progress in the treatment of ovarian cancer-lessons from homologous recombination deficiency-the first 10 years. Ann Oncol 2016;27 Suppl 1:i1-3. [PMID: 27141062 DOI: 10.1093/annonc/mdw082] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
162 Mariappan L, Jiang XY, Jackson J, Drew Y. Emerging treatment options for ovarian cancer: focus on rucaparib. Int J Womens Health 2017;9:913-24. [PMID: 29290694 DOI: 10.2147/IJWH.S151194] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
163 Hatano Y, Tamada M, Asano N, Hayasaki Y, Tomita H, Morishige KI, Hara A. High-grade serous ovarian carcinoma with mucinous differentiation: report of a rare and unique case suggesting transition from the "SET" feature of high-grade serous carcinoma to the "STEM" feature. Diagn Pathol 2019;14:4. [PMID: 30636633 DOI: 10.1186/s13000-019-0781-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
164 Boussios S, Moschetta M, Karihtala P, Samartzis EP, Sheriff M, Pappas-Gogos G, Ozturk MA, Uccello M, Karathanasi A, Tringos M, Rassy E, Pavlidis N. Development of new poly(ADP-ribose) polymerase (PARP) inhibitors in ovarian cancer: Quo Vadis? Ann Transl Med 2020;8:1706. [PMID: 33490218 DOI: 10.21037/atm.2020.03.156] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
165 Basu B, Sandhu SK, de Bono JS. PARP inhibitors: mechanism of action and their potential role in the prevention and treatment of cancer. Drugs 2012;72:1579-90. [PMID: 22834679 DOI: 10.2165/11635510-000000000-00000] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 2.3] [Reference Citation Analysis]
166 Pan Z, Xie X. BRCA mutations in the manifestation and treatment of ovarian cancer. Oncotarget 2017;8:97657-70. [PMID: 29228641 DOI: 10.18632/oncotarget.18280] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
167 Lee JM, Peer CJ, Yu M, Amable L, Gordon N, Annunziata CM, Houston N, Goey AK, Sissung TM, Parker B, Minasian L, Chiou VL, Murphy RF, Widemann BC, Figg WD, Kohn EC. Sequence-Specific Pharmacokinetic and Pharmacodynamic Phase I/Ib Study of Olaparib Tablets and Carboplatin in Women's Cancer. Clin Cancer Res 2017;23:1397-406. [PMID: 27663600 DOI: 10.1158/1078-0432.CCR-16-1546] [Cited by in Crossref: 25] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
168 Lorusso D, Maltese G, Sabatucci I, Cresta S, Matteo C, Ceruti T, D'Incalci M, Zucchetti M, Raspagliesi F, Sonetto C, Sinno V, Ronzulli D, Giolitto S, de Braud F. Phase I Study of Rucaparib in Combination with Bevacizumab in Ovarian Cancer Patients: Maximum Tolerated Dose and Pharmacokinetic Profile. Target Oncol 2021;16:59-68. [PMID: 33369704 DOI: 10.1007/s11523-020-00780-4] [Reference Citation Analysis]
169 Powers E, Karachaliou GS, Kao C, Harrison MR, Hoimes CJ, George DJ, Armstrong AJ, Zhang T. Novel therapies are changing treatment paradigms in metastatic prostate cancer. J Hematol Oncol 2020;13:144. [PMID: 33115529 DOI: 10.1186/s13045-020-00978-z] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 21.0] [Reference Citation Analysis]
170 Lord CJ, Ashworth A. PARP inhibitors: Synthetic lethality in the clinic. Science 2017;355:1152-8. [PMID: 28302823 DOI: 10.1126/science.aam7344] [Cited by in Crossref: 882] [Cited by in F6Publishing: 728] [Article Influence: 220.5] [Reference Citation Analysis]
171 Cheng H, Yang J, Liu H, Xiang Y. Poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitors as maintenance therapy in women with newly diagnosed ovarian cancer: a systematic review and meta-analysis. Arch Gynecol Obstet 2021;304:285-96. [PMID: 34021367 DOI: 10.1007/s00404-021-06070-2] [Reference Citation Analysis]
172 Nishio S, Takekuma M, Takeuchi S, Kawano K, Tsuda N, Tasaki K, Takahashi N, Abe M, Tanaka A, Nagasawa T, Shoji T, Xiong H, Nuthalapati S, Leahy T, Hashiba H, Kiriyama T, Komarnitsky P, Hirashima Y, Ushijima K. Phase 1 study of veliparib with carboplatin and weekly paclitaxel in Japanese patients with newly diagnosed ovarian cancer. Cancer Sci 2017;108:2213-20. [PMID: 28837250 DOI: 10.1111/cas.13381] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
173 Wong Te Fong AC, Thavasu P, Gagrica S, Swales KE, Leach MO, Cosulich SC, Chung YL, Banerji U. Evaluation of the combination of the dual m-TORC1/2 inhibitor vistusertib (AZD2014) and paclitaxel in ovarian cancer models. Oncotarget 2017;8:113874-84. [PMID: 29371953 DOI: 10.18632/oncotarget.23022] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
174 Dietel M, Jöhrens K, Laffert MV, Hummel M, Bläker H, Pfitzner BM, Lehmann A, Denkert C, Darb-Esfahani S, Lenze D, Heppner FL, Koch A, Sers C, Klauschen F, Anagnostopoulos I. A 2015 update on predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance. Cancer Gene Ther 2015;22:417-30. [PMID: 26358176 DOI: 10.1038/cgt.2015.39] [Cited by in Crossref: 82] [Cited by in F6Publishing: 72] [Article Influence: 13.7] [Reference Citation Analysis]
175 Ke FY, Chen WY, Lin MC, Hwang YC, Kuo KT, Wu HC. Novel monoclonal antibody against integrin α3 shows therapeutic potential for ovarian cancer. Cancer Sci 2020;111:3478-92. [PMID: 32648337 DOI: 10.1111/cas.14566] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
176 Zhou D, Li J, Bui K, Learoyd M, Berges A, Milenkova T, Al-Huniti N, Tomkinson H, Xu H. Bridging Olaparib Capsule and Tablet Formulations Using Population Pharmacokinetic Meta-analysis in Oncology Patients. Clin Pharmacokinet 2019;58:615-25. [PMID: 30357650 DOI: 10.1007/s40262-018-0714-x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 11.0] [Reference Citation Analysis]
177 Tewari KS, Sill MW, Coleman RL, Aghajanian C, Mannel R, DiSilvestro PA, Powell M, Randall LM, Farley J, Rubin SC, Monk BJ. Bevacizumab plus fosbretabulin in recurrent ovarian cancer: Overall survival and exploratory analyses of a randomized phase II NRG oncology/gynecologic oncology group study. Gynecol Oncol 2020;159:79-87. [PMID: 32723679 DOI: 10.1016/j.ygyno.2020.07.015] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
178 Li D, Hong X, Zhao F, Ci X, Zhang S. Targeting Nrf2 may reverse the drug resistance in ovarian cancer. Cancer Cell Int 2021;21:116. [PMID: 33596893 DOI: 10.1186/s12935-021-01822-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
179 Ledermann JA, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott C, Meier W, Shapira-Frommer R, Safra T, Matei D, Fielding A, Bennett B, Parry D, Spencer S, Mann H, Matulonis U. Quality of life during olaparib maintenance therapy in platinum-sensitive relapsed serous ovarian cancer. Br J Cancer 2016;115:1313-20. [PMID: 27824811 DOI: 10.1038/bjc.2016.348] [Cited by in Crossref: 34] [Cited by in F6Publishing: 29] [Article Influence: 6.8] [Reference Citation Analysis]
180 Mazzotta A, Partipilo G, De Summa S, Giotta F, Simone G, Mangia A. Nuclear PARP1 expression and its prognostic significance in breast cancer patients. Tumour Biol 2016;37:6143-53. [PMID: 26614429 DOI: 10.1007/s13277-015-4465-0] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.2] [Reference Citation Analysis]
181 Clements KE, Schleicher EM, Thakar T, Hale A, Dhoonmoon A, Tolman NJ, Sharma A, Liang X, Imamura Kawasawa Y, Nicolae CM, Wang HG, De S, Moldovan GL. Identification of regulators of poly-ADP-ribose polymerase inhibitor response through complementary CRISPR knockout and activation screens. Nat Commun 2020;11:6118. [PMID: 33257658 DOI: 10.1038/s41467-020-19961-w] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
182 Plaskocinska I, Shipman H, Drummond J, Thompson E, Buchanan V, Newcombe B, Hodgkin C, Barter E, Ridley P, Ng R, Miller S, Dann A, Licence V, Webb H, Tan LT, Daly M, Ayers S, Rufford B, Earl H, Parkinson C, Duncan T, Jimenez-Linan M, Sagoo GS, Abbs S, Hulbert-Williams N, Pharoah P, Crawford R, Brenton JD, Tischkowitz M. New paradigms for BRCA1/BRCA2 testing in women with ovarian cancer: results of the Genetic Testing in Epithelial Ovarian Cancer (GTEOC) study. J Med Genet 2016;53:655-61. [PMID: 27208206 DOI: 10.1136/jmedgenet-2016-103902] [Cited by in Crossref: 34] [Cited by in F6Publishing: 29] [Article Influence: 6.8] [Reference Citation Analysis]
183 Elyashiv O, Wong YNS, Ledermann JA. Frontline Maintenance Treatment for Ovarian Cancer. Curr Oncol Rep 2021;23:97. [PMID: 34125335 DOI: 10.1007/s11912-021-01088-w] [Reference Citation Analysis]
184 Scott CL, Swisher EM, Kaufmann SH. Poly (ADP-ribose) polymerase inhibitors: recent advances and future development. J Clin Oncol 2015;33:1397-406. [PMID: 25779564 DOI: 10.1200/JCO.2014.58.8848] [Cited by in Crossref: 223] [Cited by in F6Publishing: 131] [Article Influence: 37.2] [Reference Citation Analysis]
185 Pilié PG, Tang C, Mills GB, Yap TA. State-of-the-art strategies for targeting the DNA damage response in cancer. Nat Rev Clin Oncol 2019;16:81-104. [PMID: 30356138 DOI: 10.1038/s41571-018-0114-z] [Cited by in Crossref: 285] [Cited by in F6Publishing: 230] [Article Influence: 142.5] [Reference Citation Analysis]
186 Kroeger PT, Drapkin R. Pathogenesis and heterogeneity of ovarian cancer. Curr Opin Obstet Gynecol. 2017;29:26-34. [PMID: 27898521 DOI: 10.1097/gco.0000000000000340] [Cited by in Crossref: 96] [Cited by in F6Publishing: 63] [Article Influence: 24.0] [Reference Citation Analysis]
187 Cortesi L, Piombino C, Toss A. Germline Mutations in Other Homologous Recombination Repair-Related Genes Than BRCA1/2: Predictive or Prognostic Factors? J Pers Med 2021;11:245. [PMID: 33800556 DOI: 10.3390/jpm11040245] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
188 Santandrea G, Piana S, Valli R, Zanelli M, Gasparini E, De Leo A, Mandato VD, Palicelli A. Immunohistochemical Biomarkers as a Surrogate of Molecular Analysis in Ovarian Carcinomas: A Review of the Literature. Diagnostics (Basel) 2021;11:199. [PMID: 33572888 DOI: 10.3390/diagnostics11020199] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
189 van der Noll R, Marchetti S, Steeghs N, Beijnen JH, Mergui-Roelvink MW, Harms E, Rehorst H, Sonke GS, Schellens JH. Long-term safety and anti-tumour activity of olaparib monotherapy after combination with carboplatin and paclitaxel in patients with advanced breast, ovarian or fallopian tube cancer. Br J Cancer 2015;113:396-402. [PMID: 26180927 DOI: 10.1038/bjc.2015.256] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 5.3] [Reference Citation Analysis]
190 Stefansson OA, Villanueva A, Vidal A, Martí L, Esteller M. BRCA1 epigenetic inactivation predicts sensitivity to platinum-based chemotherapy in breast and ovarian cancer. Epigenetics. 2012;7:1225-1229. [PMID: 23069641 DOI: 10.4161/epi.22561] [Cited by in Crossref: 88] [Cited by in F6Publishing: 67] [Article Influence: 9.8] [Reference Citation Analysis]
191 Abdullah MI, Abed MN, Richardson A. Inhibition of the mevalonate pathway augments the activity of pitavastatin against ovarian cancer cells. Sci Rep 2017;7:8090. [PMID: 28808351 DOI: 10.1038/s41598-017-08649-9] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
192 Corrales-Sánchez V, Noblejas-López MDM, Nieto-Jiménez C, Pérez-Peña J, Montero JC, Burgos M, Galán-Moya EM, Pandiella A, Ocaña A. Pharmacological screening and transcriptomic functional analyses identify a synergistic interaction between dasatinib and olaparib in triple-negative breast cancer. J Cell Mol Med 2020;24:3117-27. [PMID: 32032474 DOI: 10.1111/jcmm.14980] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
193 Murthy P, Muggia F. Women's cancers: how the discovery of BRCA genes is driving current concepts of cancer biology and therapeutics. Ecancermedicalscience 2019;13:904. [PMID: 30915162 DOI: 10.3332/ecancer.2019.904] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
194 Weberpals JI, Pugh TJ, Marco-Casanova P, Goss GD, Andrews Wright N, Rath P, Torchia J, Fortuna A, Jones GN, Roudier MP, Bernard L, Lo B, Torti D, Leon A, Marsh K, Hodgson D, Duciaume M, Howat WJ, Lukashchuk N, Lazic SE, Whelan D, Sekhon HS. Tumor genomic, transcriptomic, and immune profiling characterizes differential response to first-line platinum chemotherapy in high grade serous ovarian cancer. Cancer Med 2021;10:3045-58. [PMID: 33811746 DOI: 10.1002/cam4.3831] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
195 Mann M, Kumar S, Sharma A, Chauhan SS, Bhatla N, Kumar S, Bakhshi S, Gupta R, Kumar L. PARP-1 inhibitor modulate β-catenin signaling to enhance cisplatin sensitivity in cancer cervix. Oncotarget 2019;10:4262-75. [PMID: 31303961 DOI: 10.18632/oncotarget.27008] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
196 McCann KE, Hurvitz SA. Advances in the use of PARP inhibitor therapy for breast cancer. Drugs Context 2018;7:212540. [PMID: 30116283 DOI: 10.7573/dic.212540] [Cited by in Crossref: 57] [Cited by in F6Publishing: 43] [Article Influence: 19.0] [Reference Citation Analysis]
197 Sethi GS, Dharwal V, Naura AS. Poly(ADP-Ribose)Polymerase-1 in Lung Inflammatory Disorders: A Review. Front Immunol 2017;8:1172. [PMID: 28974953 DOI: 10.3389/fimmu.2017.01172] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 7.0] [Reference Citation Analysis]
198 Oaknin A, Guarch R, Barretina P, Hardisson D, González-Martín A, Matías-Guiu X, Pérez-Fidalgo A, Vieites B, Romero I, Palacios J. Recommendations for biomarker testing in epithelial ovarian cancer: a National Consensus Statement by the Spanish Society of Pathology and the Spanish Society of Medical Oncology. Clin Transl Oncol 2018;20:274-85. [PMID: 28815456 DOI: 10.1007/s12094-017-1719-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
199 Liu FW, Tewari KS. New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors. Curr Treat Options Oncol 2016;17:12. [PMID: 26931795 DOI: 10.1007/s11864-015-0378-9] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 4.6] [Reference Citation Analysis]
200 Tsai CY, Sun S, Zhang H, Local A, Su Y, Gross LA, Rice WG, Howell SB. APTO-253 Is a New Addition to the Repertoire of Drugs that Can Exploit DNA BRCA1/2 Deficiency. Mol Cancer Ther 2018;17:1167-76. [PMID: 29626126 DOI: 10.1158/1535-7163.MCT-17-0834] [Cited by in Crossref: 11] [Cited by in F6Publishing: 1] [Article Influence: 3.7] [Reference Citation Analysis]
201 Sistigu A, Manic G, Obrist F, Vitale I. Trial watch - inhibiting PARP enzymes for anticancer therapy. Mol Cell Oncol 2016;3:e1053594. [PMID: 27308587 DOI: 10.1080/23723556.2015.1053594] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
202 Sumanasuriya S, De Bono J. Treatment of Advanced Prostate Cancer-A Review of Current Therapies and Future Promise. Cold Spring Harb Perspect Med 2018;8:a030635. [PMID: 29101113 DOI: 10.1101/cshperspect.a030635] [Cited by in Crossref: 50] [Cited by in F6Publishing: 44] [Article Influence: 16.7] [Reference Citation Analysis]
203 Dal Molin GZ, Westin SN, Coleman RL. Rucaparib in ovarian cancer: extending the use of PARP inhibitors in the recurrent disease. Future Oncol 2018;14:3101-10. [PMID: 30105925 DOI: 10.2217/fon-2018-0215] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
204 Gogineni V, Morand S, Staats H, Royfman R, Devanaboyina M, Einloth K, Dever D, Stanbery L, Aaron P, Manning L, Walter A, Edelman G, Dworkin L, Nemunaitis J. Current Ovarian Cancer Maintenance Strategies and Promising New Developments. J Cancer 2021;12:38-53. [PMID: 33391401 DOI: 10.7150/jca.49406] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
205 Favier L, Truc G, Boidot R, Bengrine-Lefevre L. Long-term response to Olaparib in carcinomatous meningitis of a BRCA2 mutated ovarian cancer: A case report. Mol Clin Oncol 2020;13:73-5. [PMID: 32454976 DOI: 10.3892/mco.2020.2035] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
206 Della Pepa C, Tonini G, Pisano C, Di Napoli M, Cecere SC, Tambaro R, Facchini G, Pignata S. Ovarian cancer standard of care: are there real alternatives? Chin J Cancer 2015;34:17-27. [PMID: 25556615 DOI: 10.5732/cjc.014.10274] [Cited by in Crossref: 51] [Cited by in F6Publishing: 43] [Article Influence: 8.5] [Reference Citation Analysis]
207 Sun Y, Hu L, Zheng H, Bagnoli M, Guo Y, Rupaimoole R, Rodriguez-Aguayo C, Lopez-Berestein G, Ji P, Chen K, Sood AK, Mezzanzanica D, Liu J, Sun B, Zhang W. MiR-506 inhibits multiple targets in the epithelial-to-mesenchymal transition network and is associated with good prognosis in epithelial ovarian cancer. J Pathol 2015;235:25-36. [PMID: 25230372 DOI: 10.1002/path.4443] [Cited by in Crossref: 67] [Cited by in F6Publishing: 66] [Article Influence: 9.6] [Reference Citation Analysis]
208 Papa A, Caruso D, Strudel M, Tomao S, Tomao F. Update on Poly-ADP-ribose polymerase inhibition for ovarian cancer treatment. J Transl Med 2016;14:267. [PMID: 27634150 DOI: 10.1186/s12967-016-1027-1] [Cited by in Crossref: 48] [Cited by in F6Publishing: 50] [Article Influence: 9.6] [Reference Citation Analysis]
209 Pépin D, Sosulski A, Zhang L, Wang D, Vathipadiekal V, Hendren K, Coletti CM, Yu A, Castro CM, Birrer MJ, Gao G, Donahoe PK. AAV9 delivering a modified human Mullerian inhibiting substance as a gene therapy in patient-derived xenografts of ovarian cancer. Proc Natl Acad Sci U S A 2015;112:E4418-27. [PMID: 26216943 DOI: 10.1073/pnas.1510604112] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 5.5] [Reference Citation Analysis]
210 Zivanovic O, Chi DS, Filippova O, Randall LM, Bristow RE, O'Cearbhaill RE. It's time to warm up to hyperthermic intraperitoneal chemotherapy for patients with ovarian cancer. Gynecol Oncol 2018;151:555-61. [PMID: 30249527 DOI: 10.1016/j.ygyno.2018.09.007] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 6.3] [Reference Citation Analysis]
211 Mills K, Fuh K. Recent Advances in Understanding, Diagnosing, and Treating Ovarian Cancer. F1000Res 2017;6:84. [PMID: 28184293 DOI: 10.12688/f1000research.9977.1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
212 Zmuda F, Blair A, Liuzzi MC, Malviya G, Chalmers AJ, Lewis D, Sutherland A, Pimlott SL. An 18F-Labeled Poly(ADP-ribose) Polymerase Positron Emission Tomography Imaging Agent. J Med Chem 2018;61:4103-14. [PMID: 29630818 DOI: 10.1021/acs.jmedchem.8b00138] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 3.7] [Reference Citation Analysis]
213 Jiang X, Li W, Li X, Bai H, Zhang Z. Current status and future prospects of PARP inhibitor clinical trials in ovarian cancer. Cancer Manag Res 2019;11:4371-90. [PMID: 31191001 DOI: 10.2147/CMAR.S200524] [Cited by in Crossref: 47] [Cited by in F6Publishing: 20] [Article Influence: 23.5] [Reference Citation Analysis]
214 Fountzilas E, Kotoula V, Koliou GA, Liontos M, Papadopoulou K, Giannoulatou E, Papanikolaou A, Tikas I, Chrisafi S, Mauri D, Chatzopoulos K, Fostira F, Pectasides D, Oikonomopoulos G, Aivazi D, Andrikopoulou A, Visvikis A, Aravantinos G, Zagouri F, Fountzilas G. Tumor Genotyping and Homologous Recombination Repair Gene Variants in Patients With Epithelial Ovarian Cancer: Is Pathogenic Enough? Front Oncol 2021;11:683057. [PMID: 34141624 DOI: 10.3389/fonc.2021.683057] [Reference Citation Analysis]
215 Thibault B, Jean-Claude B. Dasatinib + Gefitinib, a non platinum-based combination with enhanced growth inhibitory, anti-migratory and anti-invasive potency against human ovarian cancer cells. J Ovarian Res 2017;10:31. [PMID: 28446239 DOI: 10.1186/s13048-017-0319-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
216 Livraghi L, Garber JE. PARP inhibitors in the management of breast cancer: current data and future prospects. BMC Med 2015;13:188. [PMID: 26268938 DOI: 10.1186/s12916-015-0425-1] [Cited by in Crossref: 160] [Cited by in F6Publishing: 138] [Article Influence: 26.7] [Reference Citation Analysis]
217 Caster JM, Sethi M, Kowalczyk S, Wang E, Tian X, Nabeel Hyder S, Wagner KT, Zhang YA, Kapadia C, Man Au K, Wang AZ. Nanoparticle delivery of chemosensitizers improve chemotherapy efficacy without incurring additional toxicity. Nanoscale 2015;7:2805-11. [PMID: 25584654 DOI: 10.1039/c4nr07102f] [Cited by in Crossref: 24] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
218 Givel AM, Kieffer Y, Scholer-Dahirel A, Sirven P, Cardon M, Pelon F, Magagna I, Gentric G, Costa A, Bonneau C, Mieulet V, Vincent-Salomon A, Mechta-Grigoriou F. miR200-regulated CXCL12β promotes fibroblast heterogeneity and immunosuppression in ovarian cancers. Nat Commun 2018;9:1056. [PMID: 29535360 DOI: 10.1038/s41467-018-03348-z] [Cited by in Crossref: 86] [Cited by in F6Publishing: 77] [Article Influence: 28.7] [Reference Citation Analysis]
219 Siavoshinia L, Jamalan M, Zeinali M, Pourshohod A, Koushki M, Moradipoodeh B, Mohammadzadeh G. Improvement of Targeted Chemotherapy of HER2-positive Ovarian Malignant Cell Line by ZHER2-Idarubicin Conjugate: An in vitro Study. Iran J Pathol 2021;16:109-18. [PMID: 33936221 DOI: 10.30699/IJP.2020.120392.2310] [Reference Citation Analysis]
220 Gu Y, Zhang M, Peng F, Fang L, Zhang Y, Liang H, Zhou W, Ao L, Guo Z. The BRCA1/2-directed miRNA signature predicts a good prognosis in ovarian cancer patients with wild-type BRCA1/2. Oncotarget 2015;6:2397-406. [PMID: 25537514 DOI: 10.18632/oncotarget.2963] [Cited by in Crossref: 21] [Cited by in F6Publishing: 25] [Article Influence: 4.2] [Reference Citation Analysis]
221 Hwang J. Beyond HER2: recent advances and future directions in targeted therapies in esophagogastric cancers. J Gastrointest Oncol 2016;7:763-70. [PMID: 27747090 DOI: 10.21037/jgo.2016.08.13] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
222 Chakrabarty A, Chakraborty S, Bhattacharya R, Chowdhury G. Senescence-Induced Chemoresistance in Triple Negative Breast Cancer and Evolution-Based Treatment Strategies. Front Oncol 2021;11:674354. [PMID: 34249714 DOI: 10.3389/fonc.2021.674354] [Reference Citation Analysis]
223 Lopez J, Banerjee S, Kaye SB. New developments in the treatment of ovarian cancer--future perspectives. Ann Oncol 2013;24 Suppl 10:x69-76. [PMID: 24265409 DOI: 10.1093/annonc/mdt475] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 3.9] [Reference Citation Analysis]
224 Ding X, Ray Chaudhuri A, Callen E, Pang Y, Biswas K, Klarmann KD, Martin BK, Burkett S, Cleveland L, Stauffer S, Sullivan T, Dewan A, Marks H, Tubbs AT, Wong N, Buehler E, Akagi K, Martin SE, Keller JR, Nussenzweig A, Sharan SK. Synthetic viability by BRCA2 and PARP1/ARTD1 deficiencies. Nat Commun 2016;7:12425. [PMID: 27498558 DOI: 10.1038/ncomms12425] [Cited by in Crossref: 84] [Cited by in F6Publishing: 76] [Article Influence: 16.8] [Reference Citation Analysis]
225 Madariaga A, Lheureux S, Oza AM. Tailoring Ovarian Cancer Treatment: Implications of BRCA1/2 Mutations. Cancers (Basel). 2019;11. [PMID: 30909618 DOI: 10.3390/cancers11030416] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 13.0] [Reference Citation Analysis]
226 Xia Q, Lu S, Ostrovsky J, McCormack SE, Falk MJ, Grant SFA. PARP-1 Inhibition Rescues Short Lifespan in Hyperglycemic C. Elegans And Improves GLP-1 Secretion in Human Cells. Aging Dis 2018;9:17-30. [PMID: 29392078 DOI: 10.14336/AD.2017.0230] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
227 Ratner ES, Sartorelli AC, Lin ZP. Poly (ADP-ribose) polymerase inhibitors: on the horizon of tailored and personalized therapies for epithelial ovarian cancer. Curr Opin Oncol 2012;24:564-71. [PMID: 22759740 DOI: 10.1097/CCO.0b013e3283564230] [Cited by in Crossref: 34] [Cited by in F6Publishing: 21] [Article Influence: 3.8] [Reference Citation Analysis]
228 Brasseur K, Gévry N, Asselin E. Chemoresistance and targeted therapies in ovarian and endometrial cancers. Oncotarget 2017;8:4008-42. [PMID: 28008141 DOI: 10.18632/oncotarget.14021] [Cited by in Crossref: 78] [Cited by in F6Publishing: 65] [Article Influence: 26.0] [Reference Citation Analysis]
229 Yin L, Liu Y, Peng Y, Peng Y, Yu X, Gao Y, Yuan B, Zhu Q, Cao T, He L, Gong Z, Sun L, Fan X, Li X. PARP inhibitor veliparib and HDAC inhibitor SAHA synergistically co-target the UHRF1/BRCA1 DNA damage repair complex in prostate cancer cells. J Exp Clin Cancer Res 2018;37:153. [PMID: 30012171 DOI: 10.1186/s13046-018-0810-7] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 8.0] [Reference Citation Analysis]
230 Kumar-Sinha C, Chinnaiyan AM. Precision oncology in the age of integrative genomics. Nat Biotechnol 2018;36:46-60. [PMID: 29319699 DOI: 10.1038/nbt.4017] [Cited by in Crossref: 62] [Cited by in F6Publishing: 44] [Article Influence: 20.7] [Reference Citation Analysis]
231 Shah MM, Dobbin ZC, Nowsheen S, Wielgos M, Katre AA, Alvarez RD, Konstantinopoulos PA, Yang ES, Landen CN. An ex vivo assay of XRT-induced Rad51 foci formation predicts response to PARP-inhibition in ovarian cancer. Gynecol Oncol 2014;134:331-7. [PMID: 24844596 DOI: 10.1016/j.ygyno.2014.05.009] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 4.0] [Reference Citation Analysis]
232 Shaw HM, Hall M. Emerging treatment options for recurrent ovarian cancer: the potential role of olaparib. Onco Targets Ther 2013;6:1197-206. [PMID: 24043945 DOI: 10.2147/OTT.S30748] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
233 Malik PS, Raina V, André N. Metronomics as maintenance treatment in oncology: time for chemo-switch. Front Oncol 2014;4:76. [PMID: 24782987 DOI: 10.3389/fonc.2014.00076] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
234 Nakamura K, Sawada K, Yoshimura A, Kinose Y, Nakatsuka E, Kimura T. Clinical relevance of circulating cell-free microRNAs in ovarian cancer. Mol Cancer 2016;15:48. [PMID: 27343009 DOI: 10.1186/s12943-016-0536-0] [Cited by in Crossref: 92] [Cited by in F6Publishing: 82] [Article Influence: 18.4] [Reference Citation Analysis]
235 Slade D. PARP and PARG inhibitors in cancer treatment. Genes Dev 2020;34:360-94. [PMID: 32029455 DOI: 10.1101/gad.334516.119] [Cited by in Crossref: 83] [Cited by in F6Publishing: 63] [Article Influence: 83.0] [Reference Citation Analysis]
236 Marques M, Beauchamp MC, Fleury H, Laskov I, Qiang S, Pelmus M, Provencher D, Mes-Masson AM, Gotlieb WH, Witcher M. Chemotherapy reduces PARP1 in cancers of the ovary: implications for future clinical trials involving PARP inhibitors. BMC Med 2015;13:217. [PMID: 26354718 DOI: 10.1186/s12916-015-0454-9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
237 Paik ES, Lee YJ, Lee JY, Shin W, Park SY, Kim SI, Kim JW, Choi CH, Kim BG. Real-World Experience of Olaparib Maintenance in High-Grade Serous Recurrent Ovarian Cancer Patients with BRCA1/2 Mutation: A Korean Multicenter Study. J Clin Med 2019;8:E1920. [PMID: 31717415 DOI: 10.3390/jcm8111920] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
238 Wilson MK, Mercieca-Bebber R, Friedlander M. A practical guide to understanding, using and including patient reported outcomes in clinical trials in ovarian cancer. J Gynecol Oncol 2018;29:e81. [PMID: 30022641 DOI: 10.3802/jgo.2018.29.e81] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
239 Whicker ME, Lin ZP, Hanna R, Sartorelli AC, Ratner ES. MK-2206 sensitizes BRCA-deficient epithelial ovarian adenocarcinoma to cisplatin and olaparib. BMC Cancer 2016;16:550. [PMID: 27465688 DOI: 10.1186/s12885-016-2598-1] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
240 Damodaran S, Berger MF, Roychowdhury S. Clinical tumor sequencing: opportunities and challenges for precision cancer medicine. Am Soc Clin Oncol Educ Book. 2015;35:e175-e182. [PMID: 25993170 DOI: 10.14694/edbook_am.2015.35.e175] [Cited by in Crossref: 30] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
241 Rossing M, Sørensen CS, Ejlertsen B, Nielsen FC. Whole genome sequencing of breast cancer. APMIS 2019;127:303-15. [PMID: 30689231 DOI: 10.1111/apm.12920] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
242 Choi YE, Battelli C, Watson J, Liu J, Curtis J, Morse AN, Matulonis UA, Chowdhury D, Konstantinopoulos PA. Sublethal concentrations of 17-AAG suppress homologous recombination DNA repair and enhance sensitivity to carboplatin and olaparib in HR proficient ovarian cancer cells. Oncotarget 2014;5:2678-87. [PMID: 24798692 DOI: 10.18632/oncotarget.1929] [Cited by in Crossref: 33] [Cited by in F6Publishing: 25] [Article Influence: 5.5] [Reference Citation Analysis]
243 Wang Y, Ung MH, Cantor S, Cheng C. Computational Investigation of Homologous Recombination DNA Repair Deficiency in Sporadic Breast Cancer. Sci Rep 2017;7:15742. [PMID: 29146938 DOI: 10.1038/s41598-017-16138-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
244 Zeng Y, Rucki AA, Che X, Zheng L. Shifting paradigm of developing biologics for the treatment of pancreatic adenocarcinoma. J Gastrointest Oncol 2017;8:441-8. [PMID: 28736631 DOI: 10.21037/jgo.2016.10.02] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
245 Benafif S, Hall M. An update on PARP inhibitors for the treatment of cancer. Onco Targets Ther 2015;8:519-28. [PMID: 25750544 DOI: 10.2147/OTT.S30793] [Cited by in Crossref: 17] [Cited by in F6Publishing: 40] [Article Influence: 2.8] [Reference Citation Analysis]
246 Morgan RD, Clamp AR, Evans DGR, Edmondson RJ, Jayson GC. PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer. Cancer Chemother Pharmacol 2018;81:647-58. [PMID: 29464354 DOI: 10.1007/s00280-018-3532-9] [Cited by in Crossref: 40] [Cited by in F6Publishing: 35] [Article Influence: 13.3] [Reference Citation Analysis]
247 Li Y, Zhao Z, Sun D, Li Y. Novel long noncoding RNA LINC02323 promotes cell growth and migration of ovarian cancer via TGF-β receptor 1 by miR-1343-3p. J Clin Lab Anal 2021;35:e23651. [PMID: 33247856 DOI: 10.1002/jcla.23651] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
248 Zhen Y, Yu Y. Proteomic Analysis of the Downstream Signaling Network of PARP1. Biochemistry 2018;57:429-40. [PMID: 29327913 DOI: 10.1021/acs.biochem.7b01022] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 6.7] [Reference Citation Analysis]
249 Au-Yeung G, Lang F, Azar WJ, Mitchell C, Jarman KE, Lackovic K, Aziz D, Cullinane C, Pearson RB, Mileshkin L, Rischin D, Karst AM, Drapkin R, Etemadmoghadam D, Bowtell DD. Selective Targeting of Cyclin E1-Amplified High-Grade Serous Ovarian Cancer by Cyclin-Dependent Kinase 2 and AKT Inhibition. Clin Cancer Res 2017;23:1862-74. [PMID: 27663592 DOI: 10.1158/1078-0432.CCR-16-0620] [Cited by in Crossref: 66] [Cited by in F6Publishing: 39] [Article Influence: 13.2] [Reference Citation Analysis]
250 Szabova L, Bupp S, Kamal M, Householder DB, Hernandez L, Schlomer JJ, Baran ML, Yi M, Stephens RM, Annunziata CM, Martin PL, Van Dyke TA, Weaver Ohler Z, Difilippantonio S. Pathway-specific engineered mouse allograft models functionally recapitulate human serous epithelial ovarian cancer. PLoS One 2014;9:e95649. [PMID: 24748377 DOI: 10.1371/journal.pone.0095649] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
251 Uehara Y, Oda K, Ikeda Y, Koso T, Tsuji S, Yamamoto S, Asada K, Sone K, Kurikawa R, Makii C, Hagiwara O, Tanikawa M, Maeda D, Hasegawa K, Nakagawa S, Wada-Hiraike O, Kawana K, Fukayama M, Fujiwara K, Yano T, Osuga Y, Fujii T, Aburatani H. Integrated copy number and expression analysis identifies profiles of whole-arm chromosomal alterations and subgroups with favorable outcome in ovarian clear cell carcinomas. PLoS One 2015;10:e0128066. [PMID: 26043110 DOI: 10.1371/journal.pone.0128066] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 4.5] [Reference Citation Analysis]
252 Pagliuca M, Buonerba C, Fizazi K, Di Lorenzo G. The Evolving Systemic Treatment Landscape for Patients with Advanced Prostate Cancer. Drugs 2019;79:381-400. [PMID: 30742279 DOI: 10.1007/s40265-019-1060-5] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
253 Owens WA, Walaszczyk A, Spyridopoulos I, Dookun E, Richardson GD. Senescence and senolytics in cardiovascular disease: Promise and potential pitfalls. Mech Ageing Dev 2021;198:111540. [PMID: 34237321 DOI: 10.1016/j.mad.2021.111540] [Reference Citation Analysis]
254 Neff RT, Senter L, Salani R. BRCA mutation in ovarian cancer: testing, implications and treatment considerations. Ther Adv Med Oncol 2017;9:519-31. [PMID: 28794804 DOI: 10.1177/1758834017714993] [Cited by in Crossref: 41] [Cited by in F6Publishing: 34] [Article Influence: 10.3] [Reference Citation Analysis]
255 McMullen M, Karakasis K, Madariaga A, Oza AM. Overcoming Platinum and PARP-Inhibitor Resistance in Ovarian Cancer. Cancers (Basel) 2020;12:E1607. [PMID: 32560564 DOI: 10.3390/cancers12061607] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 14.0] [Reference Citation Analysis]
256 Havrilesky LJ, Alvarez Secord A, Ehrisman JA, Berchuck A, Valea FA, Lee PS, Gaillard SL, Samsa GP, Cella D, Weinfurt KP, Abernethy AP, Reed SD. Patient preferences in advanced or recurrent ovarian cancer. Cancer 2014;120:3651-9. [PMID: 25091693 DOI: 10.1002/cncr.28940] [Cited by in Crossref: 48] [Cited by in F6Publishing: 41] [Article Influence: 6.9] [Reference Citation Analysis]
257 Ceccaldi R, O'Connor KW, Mouw KW, Li AY, Matulonis UA, D'Andrea AD, Konstantinopoulos PA. A unique subset of epithelial ovarian cancers with platinum sensitivity and PARP inhibitor resistance. Cancer Res 2015;75:628-34. [PMID: 25634215 DOI: 10.1158/0008-5472.CAN-14-2593] [Cited by in Crossref: 70] [Cited by in F6Publishing: 38] [Article Influence: 11.7] [Reference Citation Analysis]
258 Kim JH, Jang HJ, Kim HS, Kim BJ, Park SH. Prognostic impact of high c-Met expression in ovarian cancer: a meta-analysis. J Cancer 2018;9:3427-34. [PMID: 30310499 DOI: 10.7150/jca.26071] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
259 Li H, Liu R, Shao B, Ran R, Song G, Wang K, Shi Y, Liu J, Hu W, Chen F, Liu X, Zhang G, Zhao C, Jia R, Wang Q, Rugo HS, Zhang Y, Li G, Xu J. Phase I dose-escalation and expansion study of PARP inhibitor, fluzoparib (SHR3162), in patients with advanced solid tumors. Chin J Cancer Res 2020;32:370-82. [PMID: 32694901 DOI: 10.21147/j.issn.1000-9604.2020.03.08] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
260 Bradbury M, Borràs E, Pérez-Benavente A, Gil-Moreno A, Santamaria A, Sabidó E. Proteomic Studies on the Management of High-Grade Serous Ovarian Cancer Patients: A Mini-Review. Cancers (Basel) 2021;13:2067. [PMID: 33922979 DOI: 10.3390/cancers13092067] [Reference Citation Analysis]
261 Smeby J, Kryeziu K, Berg KCG, Eilertsen IA, Eide PW, Johannessen B, Guren MG, Nesbakken A, Bruun J, Lothe RA, Sveen A. Molecular correlates of sensitivity to PARP inhibition beyond homologous recombination deficiency in pre-clinical models of colorectal cancer point to wild-type TP53 activity. EBioMedicine 2020;59:102923. [PMID: 32799124 DOI: 10.1016/j.ebiom.2020.102923] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
262 Tamura R, Yokoyama Y, Yoshida H, Imaizumi T, Mizunuma H. 4-Methylumbelliferone inhibits ovarian cancer growth by suppressing thymidine phosphorylase expression. J Ovarian Res 2014;7:94. [PMID: 25304388 DOI: 10.1186/s13048-014-0094-2] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
263 Pietragalla A, Ciccarone F, Nero C, Scambia G, Lorusso D, Daniele G. Integration of PARP-inhibitors in ovarian cancer therapy. Exploration of Targeted Anti-tumor Therapy 2020;1:171-82. [DOI: 10.37349/etat.2020.00011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
264 Blandino G, Di Agostino S. New therapeutic strategies to treat human cancers expressing mutant p53 proteins. J Exp Clin Cancer Res 2018;37:30. [PMID: 29448954 DOI: 10.1186/s13046-018-0705-7] [Cited by in Crossref: 89] [Cited by in F6Publishing: 78] [Article Influence: 29.7] [Reference Citation Analysis]
265 Fan Y, Ying H, Wu X, Chen H, Hu Y, Zhang H, Wu L, Yang Y, Mao B, Zheng L. The mutational pattern of homologous recombination (HR)-associated genes and its relevance to the immunotherapeutic response in gastric cancer. Cancer Biol Med 2020;17:1002-13. [PMID: 33299649 DOI: 10.20892/j.issn.2095-3941.2020.0089] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
266 Thomas C, Ji Y, Lodhi N, Kotova E, Pinnola AD, Golovine K, Makhov P, Pechenkina K, Kolenko V, Tulin AV. Non-NAD-Like poly(ADP-Ribose) Polymerase-1 Inhibitors effectively Eliminate Cancer in vivo. EBioMedicine 2016;13:90-8. [PMID: 27727003 DOI: 10.1016/j.ebiom.2016.10.001] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 4.6] [Reference Citation Analysis]
267 Tappenden P, Harnan S, Ren S, Thokala P, Wong R, Mukuria C, Green C, Pledge S, Tidy J. Olaparib for Maintenance Treatment of BRCA 1 or 2 Mutated, Relapsed, Platinum-Sensitive Ovarian, Fallopian Tube and Peritoneal Cancer in People Whose Relapsed Disease has Responded to Platinum-Based Chemotherapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Pharmacoeconomics 2017;35:97-109. [PMID: 27506954 DOI: 10.1007/s40273-016-0440-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
268 Thomas A, Murai J, Pommier Y. The evolving landscape of predictive biomarkers of response to PARP inhibitors. J Clin Invest 2018;128:1727-30. [PMID: 29664016 DOI: 10.1172/JCI120388] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 7.7] [Reference Citation Analysis]
269 King MA, Pryce RL. Evidence for compliance with long-term medication: a systematic review of randomised controlled trials. Int J Clin Pharm 2014;36:128-35. [PMID: 24293307 DOI: 10.1007/s11096-013-9893-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
270 Coleman RL, Fleming GF, Brady MF, Swisher EM, Steffensen KD, Friedlander M, Okamoto A, Moore KN, Efrat Ben-Baruch N, Werner TL, Cloven NG, Oaknin A, DiSilvestro PA, Morgan MA, Nam JH, Leath CA 3rd, Nicum S, Hagemann AR, Littell RD, Cella D, Baron-Hay S, Garcia-Donas J, Mizuno M, Bell-McGuinn K, Sullivan DM, Bach BA, Bhattacharya S, Ratajczak CK, Ansell PJ, Dinh MH, Aghajanian C, Bookman MA. Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer. N Engl J Med 2019;381:2403-15. [PMID: 31562800 DOI: 10.1056/NEJMoa1909707] [Cited by in Crossref: 234] [Cited by in F6Publishing: 98] [Article Influence: 117.0] [Reference Citation Analysis]
271 Lai Z, Markovets A, Ahdesmaki M, Chapman B, Hofmann O, McEwen R, Johnson J, Dougherty B, Barrett JC, Dry JR. VarDict: a novel and versatile variant caller for next-generation sequencing in cancer research. Nucleic Acids Res 2016;44:e108. [PMID: 27060149 DOI: 10.1093/nar/gkw227] [Cited by in Crossref: 325] [Cited by in F6Publishing: 255] [Article Influence: 65.0] [Reference Citation Analysis]
272 Lorusso D, Tripodi E, Maltese G, Lepori S, Sabatucci I, Bogani G, Raspagliesi F. Spotlight on olaparib in the treatment of BRCA-mutated ovarian cancer: design, development and place in therapy. Drug Des Devel Ther 2018;12:1501-9. [PMID: 29881257 DOI: 10.2147/DDDT.S124447] [Cited by in Crossref: 22] [Cited by in F6Publishing: 9] [Article Influence: 7.3] [Reference Citation Analysis]
273 Francis J, Coakley N, Elit L, Mackay H; Gynecologic Cancer Disease Site Group. Systemic therapy for recurrent epithelial ovarian cancer: a clinical practice guideline. Curr Oncol 2017;24:e540-6. [PMID: 29270064 DOI: 10.3747/co.24.3824] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
274 Coward JI, Middleton K, Murphy F. New perspectives on targeted therapy in ovarian cancer. Int J Womens Health 2015;7:189-203. [PMID: 25678824 DOI: 10.2147/IJWH.S52379] [Cited by in Crossref: 66] [Cited by in F6Publishing: 45] [Article Influence: 11.0] [Reference Citation Analysis]
275 Colombo I, Lheureux S, Oza AM. Rucaparib: a novel PARP inhibitor for BRCA advanced ovarian cancer. Drug Des Devel Ther. 2018;12:605-617. [PMID: 29606854 DOI: 10.2147/dddt.s130809] [Cited by in Crossref: 13] [Cited by in F6Publishing: 5] [Article Influence: 4.3] [Reference Citation Analysis]
276 Maleki Vareki S, Rytelewski M, Figueredo R, Chen D, Ferguson PJ, Vincent M, Min W, Zheng X, Koropatnick J. Indoleamine 2,3-dioxygenase mediates immune-independent human tumor cell resistance to olaparib, gamma radiation, and cisplatin. Oncotarget 2014;5:2778-91. [PMID: 24784564 DOI: 10.18632/oncotarget.1916] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 4.7] [Reference Citation Analysis]
277 González-Martín A, Sánchez-Lorenzo L, Bratos R, Márquez R, Chiva L. First-line and maintenance therapy for ovarian cancer: current status and future directions. Drugs 2014;74:879-89. [PMID: 24848752 DOI: 10.1007/s40265-014-0221-9] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
278 Do K, Chen AP. Molecular pathways: targeting PARP in cancer treatment. Clin Cancer Res 2013;19:977-84. [PMID: 23269547 DOI: 10.1158/1078-0432.CCR-12-0163] [Cited by in Crossref: 56] [Cited by in F6Publishing: 26] [Article Influence: 6.2] [Reference Citation Analysis]
279 Dias MP, Moser SC, Ganesan S, Jonkers J. Understanding and overcoming resistance to PARP inhibitors in cancer therapy. Nat Rev Clin Oncol 2021. [PMID: 34285417 DOI: 10.1038/s41571-021-00532-x] [Reference Citation Analysis]
280 Baldwin P, Ohman AW, Tangutoori S, Dinulescu DM, Sridhar S. Intraperitoneal delivery of NanoOlaparib for disseminated late-stage cancer treatment. Int J Nanomedicine 2018;13:8063-74. [PMID: 30555227 DOI: 10.2147/IJN.S186881] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
281 Hong R, Ma F, Zhang W, Yu X, Li Q, Luo Y, Zhu C, Jiang W, Xu B. 53BP1 depletion causes PARP inhibitor resistance in ATM-deficient breast cancer cells. BMC Cancer 2016;16:725. [PMID: 27613518 DOI: 10.1186/s12885-016-2754-7] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 3.4] [Reference Citation Analysis]
282 Fleury H, Malaquin N, Tu V, Gilbert S, Martinez A, Olivier MA, Sauriol A, Communal L, Leclerc-Desaulniers K, Carmona E, Provencher D, Mes-Masson AM, Rodier F. Exploiting interconnected synthetic lethal interactions between PARP inhibition and cancer cell reversible senescence. Nat Commun 2019;10:2556. [PMID: 31186408 DOI: 10.1038/s41467-019-10460-1] [Cited by in Crossref: 53] [Cited by in F6Publishing: 44] [Article Influence: 26.5] [Reference Citation Analysis]
283 Dockery LE, Gunderson CC, Moore KN. Rucaparib: the past, present, and future of a newly approved PARP inhibitor for ovarian cancer. Onco Targets Ther 2017;10:3029-37. [PMID: 28790837 DOI: 10.2147/OTT.S114714] [Cited by in Crossref: 33] [Cited by in F6Publishing: 11] [Article Influence: 8.3] [Reference Citation Analysis]
284 Marth C, Hubalek M, Petru E, Polterauer S, Reinthaller A, Schauer C, Scholl-Firon T, Singer CF, Zschocke J, Zeimet AG. AGO Austria recommendations for genetic testing of patients with ovarian cancer. Wien Klin Wochenschr 2015;127:652-4. [PMID: 26109557 DOI: 10.1007/s00508-015-0814-7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 2.6] [Reference Citation Analysis]
285 Chicago Consensus Working Group. The Chicago Consensus on Peritoneal Surface Malignancies: Management of Ovarian Neoplasms. Ann Surg Oncol 2020;27:1780-7. [PMID: 32285271 DOI: 10.1245/s10434-020-08322-y] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 11.0] [Reference Citation Analysis]
286 Santana Dos Santos E, Lallemand F, Burke L, Stoppa-Lyonnet D, Brown M, Caputo SM, Rouleau E. Non-Coding Variants in BRCA1 and BRCA2 Genes: Potential Impact on Breast and Ovarian Cancer Predisposition. Cancers (Basel) 2018;10:E453. [PMID: 30453575 DOI: 10.3390/cancers10110453] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
287 Pan K, Gong J, Huynh K, Cristea M. Current Systemic Treatment Landscape of Advanced Gynecologic Malignancies. Target Oncol 2019;14:269-83. [PMID: 31069647 DOI: 10.1007/s11523-019-00641-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
288 Zujewski JA. Changing Paradigms in Breast Cancer Therapeutics: An Extended Abstract. Med Princ Pract 2016;25 Suppl 2:73-5. [PMID: 26690956 DOI: 10.1159/000443502] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
289 Klempner SJ, Myers AP, Mills GB, Westin SN. Clinical investigation of receptor and non-receptor tyrosine kinase inhibitors for the treatment of epithelial ovarian cancer. Expert Opin Pharmacother 2013;14:2171-82. [PMID: 23937415 DOI: 10.1517/14656566.2013.826650] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
290 Yang KS, Kohler RH, Landon M, Giedt R, Weissleder R. Single cell resolution in vivo imaging of DNA damage following PARP inhibition. Sci Rep 2015;5:10129. [PMID: 25984718 DOI: 10.1038/srep10129] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 5.2] [Reference Citation Analysis]
291 Chen W, Li Z, Zheng Z, Wu X. Efficacy and safety of low-dose apatinib in ovarian cancer patients with platinum-resistance or platinum-refractoriness: A single-center retrospective study. Cancer Med 2020;9:5899-907. [PMID: 32627959 DOI: 10.1002/cam4.3282] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
292 Feng FY, de Bono JS, Rubin MA, Knudsen KE. Chromatin to Clinic: The Molecular Rationale for PARP1 Inhibitor Function. Mol Cell 2015;58:925-34. [PMID: 26091341 DOI: 10.1016/j.molcel.2015.04.016] [Cited by in Crossref: 93] [Cited by in F6Publishing: 83] [Article Influence: 15.5] [Reference Citation Analysis]
293 Symeonides S, Gourley C. Ovarian Cancer Molecular Stratification and Tumor Heterogeneity: A Necessity and a Challenge. Front Oncol 2015;5:229. [PMID: 26557500 DOI: 10.3389/fonc.2015.00229] [Cited by in Crossref: 9] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
294 Kersten K, de Visser KE, van Miltenburg MH, Jonkers J. Genetically engineered mouse models in oncology research and cancer medicine. EMBO Mol Med 2017;9:137-53. [PMID: 28028012 DOI: 10.15252/emmm.201606857] [Cited by in Crossref: 172] [Cited by in F6Publishing: 133] [Article Influence: 43.0] [Reference Citation Analysis]
295 Minchom A, Aversa C, Lopez J. Dancing with the DNA damage response: next-generation anti-cancer therapeutic strategies. Ther Adv Med Oncol 2018;10:1758835918786658. [PMID: 30023007 DOI: 10.1177/1758835918786658] [Cited by in Crossref: 65] [Cited by in F6Publishing: 54] [Article Influence: 21.7] [Reference Citation Analysis]
296 Sama AR, Schilder RJ. Refractory fallopian tube carcinoma - current perspectives in pathogenesis and management. Int J Womens Health 2014;6:149-57. [PMID: 24511245 DOI: 10.2147/IJWH.S40889] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
297 Herath NI, Berthault N, Thierry S, Jdey W, Lienafa MC, Bono F, Noguiez-Hellin P, Sun JS, Dutreix M. Preclinical Studies Comparing Efficacy and Toxicity of DNA Repair Inhibitors, Olaparib, and AsiDNA, in the Treatment of Carboplatin-Resistant Tumors. Front Oncol 2019;9:1097. [PMID: 31781480 DOI: 10.3389/fonc.2019.01097] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
298 Hollis RL, Churchman M, Gourley C. Distinct implications of different BRCA mutations: efficacy of cytotoxic chemotherapy, PARP inhibition and clinical outcome in ovarian cancer. Onco Targets Ther 2017;10:2539-51. [PMID: 28546758 DOI: 10.2147/OTT.S102569] [Cited by in Crossref: 26] [Cited by in F6Publishing: 10] [Article Influence: 6.5] [Reference Citation Analysis]
299 Martinez A, Delord JP, Ayyoub M, Devaud C. Preclinical and Clinical Immunotherapeutic Strategies in Epithelial Ovarian Cancer. Cancers (Basel) 2020;12:E1761. [PMID: 32630708 DOI: 10.3390/cancers12071761] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
300 Herzog TJ, Monk BJ. Bringing new medicines to women with epithelial ovarian cancer: what is the unmet medical need? Gynecol Oncol Res Pract 2017;4:13. [PMID: 28904804 DOI: 10.1186/s40661-017-0050-0] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
301 Montemorano L, Lightfoot MD, Bixel K. Role of Olaparib as Maintenance Treatment for Ovarian Cancer: The Evidence to Date. Onco Targets Ther 2019;12:11497-506. [PMID: 31920338 DOI: 10.2147/OTT.S195552] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
302 Landrum LM, Brady WE, Armstrong DK, Moore KN, DiSilvestro PA, O'Malley DM, Tenney ME, Rose PG, Fracasso PM. A phase I trial of pegylated liposomal doxorubicin (PLD), carboplatin, bevacizumab and veliparib in recurrent, platinum-sensitive ovarian, primary peritoneal, and fallopian tube cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol 2016;140:204-9. [PMID: 26616225 DOI: 10.1016/j.ygyno.2015.11.024] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 4.0] [Reference Citation Analysis]
303 Talreja VT, Noronha V, Joshi A, Patil V, Prabhash K. An exceptional response to olaparib in relapsed and refractory BRCA2 mutated non-small cell lung cancer in hereditary breast-ovarian cancer syndrome. South Asian J Cancer 2020;9:6. [PMID: 31956609 DOI: 10.4103/sajc.sajc_157_19] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
304 Heeke AL, Pishvaian MJ, Lynce F, Xiu J, Brody JR, Chen WJ, Baker TM, Marshall JL, Isaacs C. Prevalence of Homologous Recombination-Related Gene Mutations Across Multiple Cancer Types. JCO Precis Oncol 2018;2018. [PMID: 30234181 DOI: 10.1200/PO.17.00286] [Cited by in Crossref: 56] [Cited by in F6Publishing: 64] [Article Influence: 18.7] [Reference Citation Analysis]
305 Bundred N, Gardovskis J, Jaskiewicz J, Eglitis J, Paramonov V, McCormack P, Swaisland H, Cavallin M, Parry T, Carmichael J, Dixon JM. Evaluation of the pharmacodynamics and pharmacokinetics of the PARP inhibitor olaparib: a phase I multicentre trial in patients scheduled for elective breast cancer surgery. Invest New Drugs 2013;31:949-58. [PMID: 23315029 DOI: 10.1007/s10637-012-9922-7] [Cited by in Crossref: 59] [Cited by in F6Publishing: 53] [Article Influence: 7.4] [Reference Citation Analysis]
306 Bose CK, Basu N. PARP inhibitors and more. J Turk Ger Gynecol Assoc 2015;16:107-10. [PMID: 26097394 DOI: 10.5152/jtgga.2015.15029] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
307 Kageyama SI, Junyan D, Hojo H, Motegi A, Nakamura M, Tsuchihara K, Akimoto T. PARP inhibitor olaparib sensitizes esophageal carcinoma cells to fractionated proton irradiation. J Radiat Res. 2020;61:177-186. [PMID: 31976528 DOI: 10.1093/jrr/rrz088] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
308 Mieulet V, Garnier C, Kieffer Y, Guilbert T, Nemati F, Marangoni E, Renault G, Chamming's F, Vincent-Salomon A, Mechta-Grigoriou F. Stiffness increases with myofibroblast content and collagen density in mesenchymal high grade serous ovarian cancer. Sci Rep 2021;11:4219. [PMID: 33603134 DOI: 10.1038/s41598-021-83685-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
309 Lobo M, López-Tarruella S, Luque S, Lizarraga S, Flores-Sánchez C, Bueno O, Solera J, Jerez Y, Del Val RG, Palomero MI, Cebollero M, Echavarría I, Torres G, Martín M, Márquez-Rodas I. Evaluation of Breast Cancer Patients with Genetic Risk in a University Hospital: Before and After the Implementation of a Heredofamilial Cancer Unit. J Genet Couns 2018;27:854-62. [PMID: 29247312 DOI: 10.1007/s10897-017-0187-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
310 Bast RC Jr, Matulonis UA, Sood AK, Ahmed AA, Amobi AE, Balkwill FR, Wielgos-Bonvallet M, Bowtell DDL, Brenton JD, Brugge JS, Coleman RL, Draetta GF, Doberstein K, Drapkin RI, Eckert MA, Edwards RP, Elias KM, Ennis D, Futreal A, Gershenson DM, Greenberg RA, Huntsman DG, Ji JXY, Kohn EC, Iavarone C, Lengyel ER, Levine DA, Lord CJ, Lu Z, Mills GB, Modugno F, Nelson BH, Odunsi K, Pilsworth JA, Rottapel RK, Powell DJ Jr, Shen L, Shih IM, Spriggs DR, Walton J, Zhang K, Zhang R, Zou L. Critical questions in ovarian cancer research and treatment: Report of an American Association for Cancer Research Special Conference. Cancer 2019;125:1963-72. [PMID: 30835824 DOI: 10.1002/cncr.32004] [Cited by in Crossref: 19] [Cited by in F6Publishing: 12] [Article Influence: 9.5] [Reference Citation Analysis]
311 McCarty MF, Contreras F. Increasing Superoxide Production and the Labile Iron Pool in Tumor Cells may Sensitize Them to Extracellular Ascorbate. Front Oncol 2014;4:249. [PMID: 25279352 DOI: 10.3389/fonc.2014.00249] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
312 Morosi L, Matteo C, Ceruti T, Giordano S, Ponzo M, Frapolli R, Zucchetti M, Davoli E, D'Incalci M, Ubezio P. Quantitative determination of niraparib and olaparib tumor distribution by mass spectrometry imaging. Int J Biol Sci 2020;16:1363-75. [PMID: 32210725 DOI: 10.7150/ijbs.41395] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
313 Peer CJ, Lee JM, Roth J, Rodgers L, Nguyen J, Annunziata CM, Minasian L, Kohn EC, Figg WD. Population pharmacokinetic analyses of the effect of carboplatin pretreatment on olaparib in recurrent or refractory women's cancers. Cancer Chemother Pharmacol 2017;80:165-75. [PMID: 28577239 DOI: 10.1007/s00280-017-3346-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
314 Lorusso D, Bologna A, Cecere SC, De Matteis E, Scandurra G, Zamagni C, Arcangeli V, Artioli F, Bella M, Blanco G, Cardalesi C, Casartelli C, De Vivo R, Di Napoli M, Gisone EB, Lauria R, Lissoni AA, Loizzi V, Maccaroni E, Mangili G, Marchetti C, Martella F, Naglieri E, Parolin V, Ricciardi G, Ronzino G, Salutari V, Scarfone G, Secondino S, Spagnoletti I, Tasca G, Tognon G, Guarneri V. Sharing real-world experiences to optimize the management of olaparib toxicities: a practical guidance from an Italian expert panel. Support Care Cancer 2020;28:2435-42. [PMID: 32048043 DOI: 10.1007/s00520-020-05320-4] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
315 Liang MI, Wong DH, Walsh CS, Farias-Eisner R, Cohen JG. Cancer Genetic Counseling and Testing: Perspectives of Epithelial Ovarian Cancer Patients and Gynecologic Oncology Healthcare Providers. J Genet Couns 2018;27:177-86. [PMID: 28785836 DOI: 10.1007/s10897-017-0135-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
316 Verhaak RG, Tamayo P, Yang JY, Hubbard D, Zhang H, Creighton CJ, Fereday S, Lawrence M, Carter SL, Mermel CH, Kostic AD, Etemadmoghadam D, Saksena G, Cibulskis K, Duraisamy S, Levanon K, Sougnez C, Tsherniak A, Gomez S, Onofrio R, Gabriel S, Chin L, Zhang N, Spellman PT, Zhang Y, Akbani R, Hoadley KA, Kahn A, Köbel M, Huntsman D, Soslow RA, Defazio A, Birrer MJ, Gray JW, Weinstein JN, Bowtell DD, Drapkin R, Mesirov JP, Getz G, Levine DA, Meyerson M; Cancer Genome Atlas Research Network. Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. J Clin Invest 2013;123:517-25. [PMID: 23257362 DOI: 10.1172/JCI65833] [Cited by in Crossref: 71] [Cited by in F6Publishing: 237] [Article Influence: 7.9] [Reference Citation Analysis]
317 Sipos A, Ujlaki G, Mikó E, Maka E, Szabó J, Uray K, Krasznai Z, Bai P. The role of the microbiome in ovarian cancer: mechanistic insights into oncobiosis and to bacterial metabolite signaling. Mol Med 2021;27:33. [PMID: 33794773 DOI: 10.1186/s10020-021-00295-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
318 Dungl DA, Maginn EN, Stronach EA. Preventing Damage Limitation: Targeting DNA-PKcs and DNA Double-Strand Break Repair Pathways for Ovarian Cancer Therapy. Front Oncol 2015;5:240. [PMID: 26579492 DOI: 10.3389/fonc.2015.00240] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 3.2] [Reference Citation Analysis]
319 Lim HJ, Ledger W. Targeted therapy in ovarian cancer. Womens Health (Lond) 2016;12:363-78. [PMID: 27215391 DOI: 10.2217/whe.16.4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
320 Lu TP, Kuo KT, Chen CH, Chang MC, Lin HP, Hu YH, Chiang YC, Cheng WF, Chen CA. Developing a Prognostic Gene Panel of Epithelial Ovarian Cancer Patients by a Machine Learning Model. Cancers (Basel) 2019;11:E270. [PMID: 30823599 DOI: 10.3390/cancers11020270] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
321 Zhang Z, Ma P, Jing Y, Yan Y, Cai MC, Zhang M, Zhang S, Peng H, Ji ZL, Di W, Gu Z, Gao WQ, Zhuang G. BET Bromodomain Inhibition as a Therapeutic Strategy in Ovarian Cancer by Downregulating FoxM1. Theranostics 2016;6:219-30. [PMID: 26877780 DOI: 10.7150/thno.13178] [Cited by in Crossref: 50] [Cited by in F6Publishing: 50] [Article Influence: 10.0] [Reference Citation Analysis]
322 Singh N, Pay SL, Bhandare SB, Arimpur U, Motea EA. Therapeutic Strategies and Biomarkers to Modulate PARP Activity for Targeted Cancer Therapy. Cancers (Basel) 2020;12:E972. [PMID: 32295316 DOI: 10.3390/cancers12040972] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
323 Ow SGW, Ong PY, Lee SC. Discoveries beyond BRCA1/2: Multigene testing in an Asian multi-ethnic cohort suspected of hereditary breast cancer syndrome in the real world. PLoS One 2019;14:e0213746. [PMID: 30875412 DOI: 10.1371/journal.pone.0213746] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
324 Mancari R, Cutillo G, Bruno V, Vincenzoni C, Mancini E, Baiocco E, Bruni S, Vocaturo G, Chiofalo B, Vizza E. Development of new medical treatment for epithelial ovarian cancer recurrence. Gland Surg 2020;9:1149-63. [PMID: 32953630 DOI: 10.21037/gs-20-413] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
325 Milanesio MC, Giordano S, Valabrega G. Clinical Implications of DNA Repair Defects in High-Grade Serous Ovarian Carcinomas. Cancers (Basel) 2020;12:E1315. [PMID: 32455819 DOI: 10.3390/cancers12051315] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
326 Della Pepa C, Banerjee S. Bevacizumab in combination with chemotherapy in platinum-sensitive ovarian cancer. Onco Targets Ther 2014;7:1025-32. [PMID: 24971016 DOI: 10.2147/OTT.S40527] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
327 Putri JF, Bhargava P, Dhanjal JK, Yaguchi T, Sundar D, Kaul SC, Wadhwa R. Mortaparib, a novel dual inhibitor of mortalin and PARP1, is a potential drug candidate for ovarian and cervical cancers. J Exp Clin Cancer Res 2019;38:499. [PMID: 31856867 DOI: 10.1186/s13046-019-1500-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
328 Toss A, Piombino C, Tenedini E, Bologna A, Gasparini E, Tarantino V, Filieri ME, Cottafavi L, Giovanardi F, Madrigali S, Civallero M, Marcheselli L, Marchi I, Domati F, Venturelli M, Barbieri E, Grandi G, Tagliafico E, Cortesi L. The Prognostic and Predictive Role of Somatic BRCA Mutations in Ovarian Cancer: Results from a Multicenter Cohort Study. Diagnostics (Basel) 2021;11:565. [PMID: 33801055 DOI: 10.3390/diagnostics11030565] [Reference Citation Analysis]
329 Zhou Y, Tang S, Chen T, Niu MM. Structure-Based Pharmacophore Modeling, Virtual Screening, Molecular Docking and Biological Evaluation for Identification of Potential Poly (ADP-Ribose) Polymerase-1 (PARP-1) Inhibitors. Molecules 2019;24:E4258. [PMID: 31766720 DOI: 10.3390/molecules24234258] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
330 Ghonim MA, Pyakurel K, Ibba SV, Al-Khami AA, Wang J, Rodriguez P, Rady HF, El-Bahrawy AH, Lammi MR, Mansy MS, Al-Ghareeb K, Ramsay A, Ochoa A, Naura AS, Boulares AH. PARP inhibition by olaparib or gene knockout blocks asthma-like manifestation in mice by modulating CD4(+) T cell function. J Transl Med 2015;13:225. [PMID: 26169874 DOI: 10.1186/s12967-015-0583-0] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 4.0] [Reference Citation Analysis]
331 Morice PM, Coquan E, Weiswald LB, Lambert B, Vaur D, Poulain L. Identifying patients eligible for PARP inhibitor treatment: from NGS-based tests to 3D functional assays. Br J Cancer 2021;125:7-14. [PMID: 33767416 DOI: 10.1038/s41416-021-01295-z] [Reference Citation Analysis]
332 Liu Y, Meng J, Wang G. Risk of selected gastrointestinal toxicities associated with poly (ADP-ribose) polymerase (PARP) inhibitors in the treatment of ovarian cancer: a meta-analysis of published trials. Drug Des Devel Ther 2018;12:3013-9. [PMID: 30271116 DOI: 10.2147/DDDT.S164553] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 3.7] [Reference Citation Analysis]
333 Lokadasan R, James FV, Narayanan G, Prabhakaran PK. Targeted agents in epithelial ovarian cancer: review on emerging therapies and future developments. Ecancermedicalscience 2016;10:626. [PMID: 27110282 DOI: 10.3332/ecancer.2016.626] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
334 Cerrato A, Morra F, Celetti A. Use of poly ADP-ribose polymerase [PARP] inhibitors in cancer cells bearing DDR defects: the rationale for their inclusion in the clinic. J Exp Clin Cancer Res 2016;35:179. [PMID: 27884198 DOI: 10.1186/s13046-016-0456-2] [Cited by in Crossref: 56] [Cited by in F6Publishing: 49] [Article Influence: 11.2] [Reference Citation Analysis]
335 Jubin T, Kadam A, Jariwala M, Bhatt S, Sutariya S, Gani AR, Gautam S, Begum R. The PARP family: insights into functional aspects of poly (ADP-ribose) polymerase-1 in cell growth and survival. Cell Prolif. 2016;49:421-437. [PMID: 27329285 DOI: 10.1111/cpr.12268] [Cited by in Crossref: 45] [Cited by in F6Publishing: 39] [Article Influence: 9.0] [Reference Citation Analysis]
336 Song L, McNeil EM, Ritchie AM, Astell KR, Gourley C, Melton DW. Melanoma cells replicate through chemotherapy by reducing levels of key homologous recombination protein RAD51 and increasing expression of translesion synthesis DNA polymerase ζ. BMC Cancer 2017;17:864. [PMID: 29254481 DOI: 10.1186/s12885-017-3864-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
337 Sehouli J, Braicu EI, Chekerov R. PARP Inhibitors for Recurrent Ovarian Carcinoma: Current Treatment Options and Future Perspectives. Geburtshilfe Frauenheilkd 2016;76:164-9. [PMID: 26941449 DOI: 10.1055/s-0035-1558185] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
338 Kim JY, Cho CH, Song HS. Targeted therapy of ovarian cancer including immune check point inhibitor. Korean J Intern Med 2017;32:798-804. [PMID: 28823141 DOI: 10.3904/kjim.2017.008] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 5.5] [Reference Citation Analysis]
339 Kim M, Suh DH, Lee KH, Eom KY, Toftdahl NG, Mirza MR, Kim JW. Major clinical research advances in gynecologic cancer in 2018. J Gynecol Oncol 2019;30:e18. [PMID: 30806045 DOI: 10.3802/jgo.2019.30.e18] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 8.5] [Reference Citation Analysis]
340 Ni J, Zhou R, Cheng X, Xu X, Guo W, Chen X. Tumor burden is a potential marker of PARP inhibitor effects in ovarian cancer: a head-to-head observational series. J Ovarian Res 2020;13:29. [PMID: 32183851 DOI: 10.1186/s13048-020-00629-4] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
341 Hodge DQ, Cui J, Gamble MJ, Guo W. Histone Variant MacroH2A1 Plays an Isoform-Specific Role in Suppressing Epithelial-Mesenchymal Transition. Sci Rep 2018;8:841. [PMID: 29339820 DOI: 10.1038/s41598-018-19364-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
342 Helland Ø, Popa M, Bischof K, Gjertsen BT, McCormack E, Bjørge L. The HDACi Panobinostat Shows Growth Inhibition Both In Vitro and in a Bioluminescent Orthotopic Surgical Xenograft Model of Ovarian Cancer. PLoS One 2016;11:e0158208. [PMID: 27352023 DOI: 10.1371/journal.pone.0158208] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
343 Bowtell DD, Böhm S, Ahmed AA, Aspuria PJ, Bast RC Jr, Beral V, Berek JS, Birrer MJ, Blagden S, Bookman MA, Brenton JD, Chiappinelli KB, Martins FC, Coukos G, Drapkin R, Edmondson R, Fotopoulou C, Gabra H, Galon J, Gourley C, Heong V, Huntsman DG, Iwanicki M, Karlan BY, Kaye A, Lengyel E, Levine DA, Lu KH, McNeish IA, Menon U, Narod SA, Nelson BH, Nephew KP, Pharoah P, Powell DJ Jr, Ramos P, Romero IL, Scott CL, Sood AK, Stronach EA, Balkwill FR. Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. Nat Rev Cancer 2015;15:668-79. [PMID: 26493647 DOI: 10.1038/nrc4019] [Cited by in Crossref: 488] [Cited by in F6Publishing: 416] [Article Influence: 97.6] [Reference Citation Analysis]
344 Lee JM, Hays JL, Annunziata CM, Noonan AM, Minasian L, Zujewski JA, Yu M, Gordon N, Ji J, Sissung TM. Phase I/Ib study of olaparib and carboplatin in BRCA1 or BRCA2 mutation-associated breast or ovarian cancer with biomarker analyses. J Natl Cancer Inst. 2014;106:dju089. [PMID: 24842883 DOI: 10.1093/jnci/dju089] [Cited by in Crossref: 96] [Cited by in F6Publishing: 111] [Article Influence: 13.7] [Reference Citation Analysis]
345 Curtin N, Bányai K, Thaventhiran J, Le Quesne J, Helyes Z, Bai P. Repositioning PARP inhibitors for SARS-CoV-2 infection(COVID-19); a new multi-pronged therapy for acute respiratory distress syndrome? Br J Pharmacol 2020;177:3635-45. [PMID: 32441764 DOI: 10.1111/bph.15137] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 21.0] [Reference Citation Analysis]
346 Coleman RL, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, Colombo N, Weberpals JI, Clamp A, Scambia G, Leary A, Holloway RW, Gancedo MA, Fong PC, Goh JC, O'Malley DM, Armstrong DK, Garcia-Donas J, Swisher EM, Floquet A, Konecny GE, McNeish IA, Scott CL, Cameron T, Maloney L, Isaacson J, Goble S, Grace C, Harding TC, Raponi M, Sun J, Lin KK, Giordano H, Ledermann JA; ARIEL3 investigators. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2017;390:1949-61. [PMID: 28916367 DOI: 10.1016/S0140-6736(17)32440-6] [Cited by in Crossref: 596] [Cited by in F6Publishing: 285] [Article Influence: 149.0] [Reference Citation Analysis]
347 Zhou J, Gelot C, Pantelidou C, Li A, Yücel H, Davis RE, Farkkila A, Kochupurakkal B, Syed A, Shapiro GI, Tainer JA, Blagg BSJ, Ceccaldi R, D'Andrea AD. A first-in-class Polymerase Theta Inhibitor selectively targets Homologous-Recombination-Deficient Tumors. Nat Cancer 2021;2:598-610. [PMID: 34179826 DOI: 10.1038/s43018-021-00203-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 6.0] [Reference Citation Analysis]
348 Huang XZ, Jia H, Xiao Q, Li RZ, Wang XS, Yin HY, Zhou X. Efficacy and Prognostic Factors for PARP Inhibitors in Patients With Ovarian Cancer. Front Oncol 2020;10:958. [PMID: 32612955 DOI: 10.3389/fonc.2020.00958] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
349 Garzon S, Laganà AS, Casarin J, Raffaelli R, Cromi A, Franchi M, Barra F, Alkatout I, Ferrero S, Ghezzi F. Secondary and tertiary ovarian cancer recurrence: what is the best management? Gland Surg 2020;9:1118-29. [PMID: 32953627 DOI: 10.21037/gs-20-325] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
350 Shen JP, Ideker T. Synthetic Lethal Networks for Precision Oncology: Promises and Pitfalls. J Mol Biol 2018;430:2900-12. [PMID: 29932943 DOI: 10.1016/j.jmb.2018.06.026] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 4.3] [Reference Citation Analysis]
351 Govindarajan M, Wohlmuth C, Waas M, Bernardini MQ, Kislinger T. High-throughput approaches for precision medicine in high-grade serous ovarian cancer. J Hematol Oncol 2020;13:134. [PMID: 33036656 DOI: 10.1186/s13045-020-00971-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
352 McGee J, Panabaker K, Leonard S, Ainsworth P, Elit L, Shariff SZ. Genetics Consultation Rates Following a Diagnosis of High-Grade Serous Ovarian Carcinoma in the Canadian Province of Ontario. Int J Gynecol Cancer 2017;27:437-43. [PMID: 28072594 DOI: 10.1097/IGC.0000000000000907] [Cited by in Crossref: 16] [Cited by in F6Publishing: 5] [Article Influence: 5.3] [Reference Citation Analysis]
353 Ahmed N, Kadife E, Raza A, Short M, Jubinsky PT, Kannourakis G. Ovarian Cancer, Cancer Stem Cells and Current Treatment Strategies: A Potential Role of Magmas in the Current Treatment Methods. Cells 2020;9:E719. [PMID: 32183385 DOI: 10.3390/cells9030719] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 11.0] [Reference Citation Analysis]
354 Mateo J, Carreira S, Sandhu S, Miranda S, Mossop H, Perez-Lopez R, Nava Rodrigues D, Robinson D, Omlin A, Tunariu N. DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. N Engl J Med. 2015;373:1697-1708. [PMID: 26510020 DOI: 10.1056/nejmoa1506859] [Cited by in Crossref: 1229] [Cited by in F6Publishing: 624] [Article Influence: 204.8] [Reference Citation Analysis]
355 Ahn DH, Javle M, Ahn CW, Jain A, Mikhail S, Noonan AM, Ciombor K, Wu C, Shroff RT, Chen JL, Bekaii-Saab T. Next-generation sequencing survey of biliary tract cancer reveals the association between tumor somatic variants and chemotherapy resistance. Cancer 2016;122:3657-66. [PMID: 27495988 DOI: 10.1002/cncr.30247] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 5.4] [Reference Citation Analysis]
356 Fukagawa S, Miyata K, Yotsumoto F, Kiyoshima C, Nam SO, Anan H, Katsuda T, Miyahara D, Murata M, Yagi H, Shirota K, Yasunaga S, Kato K, Miyamoto S. MicroRNA-135a-3p as a promising biomarker and nucleic acid therapeutic agent for ovarian cancer. Cancer Sci 2017;108:886-96. [PMID: 28231414 DOI: 10.1111/cas.13210] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 4.0] [Reference Citation Analysis]
357 Dréan A, Williamson CT, Brough R, Brandsma I, Menon M, Konde A, Garcia-Murillas I, Pemberton HN, Frankum J, Rafiq R, Badham N, Campbell J, Gulati A, Turner NC, Pettitt SJ, Ashworth A, Lord CJ. Modeling Therapy Resistance in BRCA1/2-Mutant Cancers. Mol Cancer Ther 2017;16:2022-34. [PMID: 28619759 DOI: 10.1158/1535-7163.MCT-17-0098] [Cited by in Crossref: 39] [Cited by in F6Publishing: 21] [Article Influence: 9.8] [Reference Citation Analysis]
358 Kemp Z, Ledermann J. Update on first-line treatment of advanced ovarian carcinoma. Int J Womens Health 2013;5:45-51. [PMID: 23378788 DOI: 10.2147/IJWH.S30231] [Cited by in Crossref: 9] [Cited by in F6Publishing: 18] [Article Influence: 1.1] [Reference Citation Analysis]
359 Hou MM, Wang Z, Janku F, Piha-Paul S, Naing A, Hong D, Westin S, Coleman RL, Sood AK, Tsimberidou AM, Subbiah V, Wheler J, Zinner R, Lu K, Meric-Bernstam F, Fu S. Continuous anti-angiogenic therapy after tumor progression in patients with recurrent high-grade epithelial ovarian cancer: phase I trial experience. Oncotarget 2016;7:35132-43. [PMID: 27147567 DOI: 10.18632/oncotarget.9048] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
360 Isakoff SJ, Puhalla S, Domchek SM, Friedlander M, Kaufman B, Robson M, Telli ML, Diéras V, Han HS, Garber JE, Johnson EF, Maag D, Qin Q, Giranda VL, Shepherd SP. A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationale. Future Oncol 2017;13:307-20. [PMID: 27739325 DOI: 10.2217/fon-2016-0412] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 5.2] [Reference Citation Analysis]
361 Lightfoot M, Montemorano L, Bixel K. PARP Inhibitors in Gynecologic Cancers: What Is the Next Big Development? Curr Oncol Rep 2020;22:29. [PMID: 32067102 DOI: 10.1007/s11912-020-0873-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
362 Hettle R, Borrill J, Suri G, Wulff J. Estimating health-state utility values for patients with recurrent ovarian cancer using Functional Assessment of Cancer Therapy - General mapping algorithms. Clinicoecon Outcomes Res 2015;7:615-27. [PMID: 26648747 DOI: 10.2147/CEOR.S92078] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
363 Pokataev I, Fedyanin M, Polyanskaya E, Popova A, Agafonova J, Menshikova S, Tryakin A, Rumyantsev A, Tjulandin S. Efficacy of platinum-based chemotherapy and prognosis of patients with pancreatic cancer with homologous recombination deficiency: comparative analysis of published clinical studies. ESMO Open 2020;5:e000578. [PMID: 33551067 DOI: 10.1136/esmoopen-2019-000578] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
364 Friedlander M, Matulonis U, Gourley C, du Bois A, Vergote I, Rustin G, Scott C, Meier W, Shapira-Frommer R, Safra T, Matei D, Shirinkin V, Selle F, Fielding A, Lowe ES, McMurtry EL, Spencer S, Rowe P, Mann H, Parry D, Ledermann J. Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy. Br J Cancer 2018;119:1075-85. [PMID: 30353045 DOI: 10.1038/s41416-018-0271-y] [Cited by in Crossref: 70] [Cited by in F6Publishing: 61] [Article Influence: 23.3] [Reference Citation Analysis]
365 Fulton B, Jones R, Powles T, Crabb S, Paul J, Birtle A, Chowdhury S, Hussain S, Morris A, Soulis E, Morrison P. ATLANTIS: a randomised multi-arm phase II biomarker-directed umbrella screening trial of maintenance targeted therapy after chemotherapy in patients with advanced or metastatic urothelial cancer. Trials 2020;21:344. [PMID: 32306987 DOI: 10.1186/s13063-020-04283-5] [Reference Citation Analysis]
366 Han B, Meng X, Wu P, Li Z, Li S, Zhang Y, Zha C, Ye Q, Jiang C, Cai J, Jiang T. ATRX/EZH2 complex epigenetically regulates FADD/PARP1 axis, contributing to TMZ resistance in glioma. Theranostics 2020;10:3351-65. [PMID: 32194873 DOI: 10.7150/thno.41219] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 15.0] [Reference Citation Analysis]
367 Poveda A, Oaknin A, Romero I, Guerrero-Zotano A, Fariñas-Madrid L, Rodriguez-Freixinos V, Mallol P, Lopez-Reig R, Lopez-Guerrero JA. A phase I dose-finding, pharmacokinetics and genotyping study of olaparib and lurbinectedin in patients with advanced solid tumors. Sci Rep 2021;11:4433. [PMID: 33627685 DOI: 10.1038/s41598-021-82671-w] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
368 Alyateem G, Nilubol N. Current Status and Future Targeted Therapy in Adrenocortical Cancer. Front Endocrinol (Lausanne) 2021;12:613248. [PMID: 33732213 DOI: 10.3389/fendo.2021.613248] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
369 Lodhia KA, Hadley AM, Haluska P, Scott CL. Prioritizing therapeutic targets using patient-derived xenograft models. Biochim Biophys Acta 2015;1855:223-34. [PMID: 25783201 DOI: 10.1016/j.bbcan.2015.03.002] [Cited by in Crossref: 10] [Cited by in F6Publishing: 19] [Article Influence: 1.7] [Reference Citation Analysis]
370 Liu J, Wang Q, Zhang R, Zhang C, Lin J, Huang X. Identification of LINC01279 as a cell cycle‑associated long non‑coding RNA in endometriosis with GBA analysis. Mol Med Rep 2018;18:3850-8. [PMID: 30106115 DOI: 10.3892/mmr.2018.9387] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
371 Davies H, Glodzik D, Morganella S, Yates LR, Staaf J, Zou X, Ramakrishna M, Martin S, Boyault S, Sieuwerts AM, Simpson PT, King TA, Raine K, Eyfjord JE, Kong G, Borg Å, Birney E, Stunnenberg HG, van de Vijver MJ, Børresen-Dale AL, Martens JW, Span PN, Lakhani SR, Vincent-Salomon A, Sotiriou C, Tutt A, Thompson AM, Van Laere S, Richardson AL, Viari A, Campbell PJ, Stratton MR, Nik-Zainal S. HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures. Nat Med 2017;23:517-25. [PMID: 28288110 DOI: 10.1038/nm.4292] [Cited by in Crossref: 365] [Cited by in F6Publishing: 276] [Article Influence: 91.3] [Reference Citation Analysis]
372 Principe DR, Kamath SD, Munshi HG, Mohindra NA. Metastatic Thymoma Harboring a Deleterious BRCA2 Mutation Derives Durable Clinical Benefit from Olaparib. Oncologist 2020;25:301-5. [PMID: 32297440 DOI: 10.1634/theoncologist.2019-0393] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
373 Prasad CB, Prasad SB, Yadav SS, Pandey LK, Singh S, Pradhan S, Narayan G. Olaparib modulates DNA repair efficiency, sensitizes cervical cancer cells to cisplatin and exhibits anti-metastatic property. Sci Rep 2017;7:12876. [PMID: 28993682 DOI: 10.1038/s41598-017-13232-3] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 7.0] [Reference Citation Analysis]
374 Maxwell KN, Domchek SM. Cancer treatment according to BRCA1 and BRCA2 mutations. Nat Rev Clin Oncol 2012;9:520-8. [PMID: 22825375 DOI: 10.1038/nrclinonc.2012.123] [Cited by in Crossref: 52] [Cited by in F6Publishing: 47] [Article Influence: 5.8] [Reference Citation Analysis]
375 Moore KN, Birrer MJ. Administration of the Tablet Formulation of Olaparib in Patients with Ovarian Cancer: Practical Guidance and Expectations. Oncologist 2018;23:697-703. [PMID: 29593098 DOI: 10.1634/theoncologist.2017-0485] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
376 de Haan R, van Werkhoven E, van den Heuvel MM, Peulen HMU, Sonke GS, Elkhuizen P, van den Brekel MWM, Tesselaar MET, Vens C, Schellens JHM, van Triest B, Verheij M. Study protocols of three parallel phase 1 trials combining radical radiotherapy with the PARP inhibitor olaparib. BMC Cancer 2019;19:901. [PMID: 31500595 DOI: 10.1186/s12885-019-6121-3] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 7.5] [Reference Citation Analysis]
377 Markman M. Ovarian cancer survival: steady improvement, despite rhetoric to the contrary. Curr Oncol Rep 2013;15:433-5. [PMID: 23933889 DOI: 10.1007/s11912-013-0338-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
378 Zhou JX, Feng LJ, Zhang X. Risk of severe hematologic toxicities in cancer patients treated with PARP inhibitors: a meta-analysis of randomized controlled trials. Drug Des Devel Ther 2017;11:3009-17. [PMID: 29075104 DOI: 10.2147/DDDT.S147726] [Cited by in Crossref: 32] [Cited by in F6Publishing: 18] [Article Influence: 8.0] [Reference Citation Analysis]
379 Lim JSJ, Tan DSP. Understanding Resistance Mechanisms and Expanding the Therapeutic Utility of PARP Inhibitors. Cancers (Basel) 2017;9:E109. [PMID: 28829366 DOI: 10.3390/cancers9080109] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 4.8] [Reference Citation Analysis]
380 Boussios S, Karathanasi A, Cooke D, Neille C, Sadauskaite A, Moschetta M, Zakynthinakis-Kyriakou N, Pavlidis N. PARP Inhibitors in Ovarian Cancer: The Route to "Ithaca". Diagnostics (Basel) 2019;9:E55. [PMID: 31109041 DOI: 10.3390/diagnostics9020055] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 10.5] [Reference Citation Analysis]
381 Guo X, Mei J, Jing Y, Wang S. Curcumin-Loaded Nanoparticles with Low-Intensity Focused Ultrasound-Induced Phase Transformation as Tumor-Targeted and pH-Sensitive Theranostic Nanoplatform of Ovarian Cancer. Nanoscale Res Lett 2020;15:73. [PMID: 32266591 DOI: 10.1186/s11671-020-03302-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
382 Malaquin N, Vancayseele A, Gilbert S, Antenor-Habazac L, Olivier MA, Ait Ali Brahem Z, Saad F, Delouya G, Rodier F. DNA Damage- But Not Enzalutamide-Induced Senescence in Prostate Cancer Promotes Senolytic Bcl-xL Inhibitor Sensitivity. Cells 2020;9:E1593. [PMID: 32630281 DOI: 10.3390/cells9071593] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
383 Konstantinopoulos PA, Wilson AJ, Saskowski J, Wass E, Khabele D. Suberoylanilide hydroxamic acid (SAHA) enhances olaparib activity by targeting homologous recombination DNA repair in ovarian cancer. Gynecol Oncol 2014;133:599-606. [PMID: 24631446 DOI: 10.1016/j.ygyno.2014.03.007] [Cited by in Crossref: 67] [Cited by in F6Publishing: 59] [Article Influence: 9.6] [Reference Citation Analysis]
384 Majić A, Miše BP, Matković V, Belac Lovasić I, Katić K, Canjko I, Frobe A, Bajić Ž, Vrdoljak E. Olaparib Outcomes in Patients with BRCA 1-2 Mutated, Platinum-Sensitive, Recurrent Ovarian Cancer in Croatia: A Retrospective Noninterventional Study. J Oncol 2020;2020:6423936. [PMID: 32655639 DOI: 10.1155/2020/6423936] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
385 Tomao F, Boccia SM, Sassu CM, Chirra M, Palaia I, Petrella MC, Di Donato V, Colombo N, Benedetti Panici P. First-Line Treatment  with Olaparib for Early Stage BRCA-Positive Ovarian Cancer: May It Be Possible? Hypothesis Potentially Generating a Line of Research. Cancer Manag Res 2020;12:5479-89. [PMID: 32765062 DOI: 10.2147/CMAR.S194874] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
386 Sekine M, Nishino K, Enomoto T. BRCA Genetic Test and Risk-Reducing Salpingo-Oophorectomy for Hereditary Breast and Ovarian Cancer: State-of-the-Art. Cancers (Basel) 2021;13:2562. [PMID: 34071148 DOI: 10.3390/cancers13112562] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
387 Hufnagel DH, Wilson AJ, Saxon J, Blackwell TS, Watkins J, Khabele D, Crispens MA, Yull FE, Beeghly-Fadiel A. Expression of p52, a non-canonical NF-kappaB transcription factor, is associated with poor ovarian cancer prognosis. Biomark Res 2020;8:45. [PMID: 32974032 DOI: 10.1186/s40364-020-00227-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
388 Zhu Y, Liu J, Park J, Rai P, Zhai RG. Subcellular compartmentalization of NAD+ and its role in cancer: A sereNADe of metabolic melodies. Pharmacol Ther 2019;200:27-41. [PMID: 30974124 DOI: 10.1016/j.pharmthera.2019.04.002] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 11.0] [Reference Citation Analysis]
389 Sultova E, Westphalen CB, Jung A, Kumbrink J, Kirchner T, Mayr D, Rudelius M, Ormanns S, Heinemann V, Metzeler KH, Greif PA, Burges A, Trillsch F, Mahner S, Harbeck N, Wuerstlein R. NGS-guided precision oncology in metastatic breast and gynecological cancer: first experiences at the CCC Munich LMU. Arch Gynecol Obstet 2021;303:1331-45. [PMID: 33277683 DOI: 10.1007/s00404-020-05881-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
390 Maxwell KN, Wubbenhorst B, Wenz BM, De Sloover D, Pluta J, Emery L, Barrett A, Kraya AA, Anastopoulos IN, Yu S, Jiang Y, Chen H, Zhang NR, Hackman N, D'Andrea K, Daber R, Morrissette JJD, Mitra N, Feldman M, Domchek SM, Nathanson KL. BRCA locus-specific loss of heterozygosity in germline BRCA1 and BRCA2 carriers. Nat Commun. 2017;8:319. [PMID: 28831036 DOI: 10.1038/s41467-017-00388-9] [Cited by in Crossref: 116] [Cited by in F6Publishing: 93] [Article Influence: 29.0] [Reference Citation Analysis]
391 van Wijk LM, Vermeulen S, Meijers M, van Diest MF, Ter Haar NT, de Jonge MM, Solleveld-Westerink N, van Wezel T, van Gent DC, Kroep JR, Bosse T, Gaarenstroom KN, Vrieling H, Vreeswijk MPG. The RECAP Test Rapidly and Reliably Identifies Homologous Recombination-Deficient Ovarian Carcinomas. Cancers (Basel) 2020;12:E2805. [PMID: 33003546 DOI: 10.3390/cancers12102805] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
392 Evans T, Matulonis U. PARP inhibitors in ovarian cancer: evidence, experience and clinical potential. Ther Adv Med Oncol 2017;9:253-67. [PMID: 28491146 DOI: 10.1177/1758834016687254] [Cited by in Crossref: 55] [Cited by in F6Publishing: 47] [Article Influence: 13.8] [Reference Citation Analysis]
393 Ke Y, Wang C, Zhang J, Zhong X, Wang R, Zeng X, Ba X. The Role of PARPs in Inflammation-and Metabolic-Related Diseases: Molecular Mechanisms and Beyond. Cells 2019;8:E1047. [PMID: 31500199 DOI: 10.3390/cells8091047] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 13.5] [Reference Citation Analysis]
394 Yan S, Frank D, Son J, Hannan KM, Hannan RD, Chan KT, Pearson RB, Sanij E. The Potential of Targeting Ribosome Biogenesis in High-Grade Serous Ovarian Cancer. Int J Mol Sci 2017;18:E210. [PMID: 28117679 DOI: 10.3390/ijms18010210] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
395 Tortorella L, Vizzielli G, Fusco D, Cho WC, Bernabei R, Scambia G, Colloca G. Ovarian Cancer Management in the Oldest Old: Improving Outcomes and Tailoring Treatments. Aging Dis 2017;8:677-84. [PMID: 28966809 DOI: 10.14336/AD.2017.0607] [Cited by in Crossref: 19] [Cited by in F6Publishing: 11] [Article Influence: 4.8] [Reference Citation Analysis]
396 Correa RJ, Valdes YR, Peart TM, Fazio EN, Bertrand M, McGee J, Préfontaine M, Sugimoto A, DiMattia GE, Shepherd TG. Combination of AKT inhibition with autophagy blockade effectively reduces ascites-derived ovarian cancer cell viability. Carcinogenesis 2014;35:1951-61. [PMID: 24562574 DOI: 10.1093/carcin/bgu049] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 5.0] [Reference Citation Analysis]
397 Nunes T, Hamdan D, Leboeuf C, El Bouchtaoui M, Gapihan G, Nguyen TT, Meles S, Angeli E, Ratajczak P, Lu H, Di Benedetto M, Bousquet G, Janin A. Targeting Cancer Stem Cells to Overcome Chemoresistance. Int J Mol Sci 2018;19:E4036. [PMID: 30551640 DOI: 10.3390/ijms19124036] [Cited by in Crossref: 53] [Cited by in F6Publishing: 39] [Article Influence: 17.7] [Reference Citation Analysis]
398 Gupta M, Iyer R, Fountzilas C. Poly(ADP-Ribose) Polymerase Inhibitors in Pancreatic Cancer: A New Treatment Paradigms and Future Implications. Cancers (Basel) 2019;11:E1980. [PMID: 31835379 DOI: 10.3390/cancers11121980] [Cited by in Crossref: 18] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
399 Lisio MA, Fu L, Goyeneche A, Gao ZH, Telleria C. High-Grade Serous Ovarian Cancer: Basic Sciences, Clinical and Therapeutic Standpoints. Int J Mol Sci 2019;20:E952. [PMID: 30813239 DOI: 10.3390/ijms20040952] [Cited by in Crossref: 104] [Cited by in F6Publishing: 69] [Article Influence: 52.0] [Reference Citation Analysis]
400 Kurnit KC, Avila M, Hinchcliff EM, Coleman RL, Westin SN. PARP inhibition in the ovarian cancer patient: Current approvals and future directions. Pharmacol Ther 2020;213:107588. [PMID: 32450190 DOI: 10.1016/j.pharmthera.2020.107588] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
401 Lasala R, Santoleri F, Romagnoli A, Musicco F, Costantini A. Dosage adjustments in pivotal clinical trials with oral targeted therapies in solid tumors conducted in Europe. Eur J Clin Pharmacol 2019;75:697-706. [PMID: 30617511 DOI: 10.1007/s00228-018-02621-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
402 Solano AR, Liria NC, Jalil FS, Faggionato DM, Mele PG, Mampel A, Cardoso FC, Podesta EJ. BRCA1 and BRCA2 Mutations Other Than the Founder Alleles Among Ashkenazi Jewish in the Population of Argentina. Front Oncol 2018;8:323. [PMID: 30186769 DOI: 10.3389/fonc.2018.00323] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.7] [Reference Citation Analysis]
403 Radl B, Mlineritsch B. ASCO 2017-highlights of gynecological cancer. Memo 2017;10:237-9. [PMID: 29250203 DOI: 10.1007/s12254-017-0371-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
404 Bercow AS, Chen L, Chatterjee S, Tergas AI, Hou JY, Burke WM, Ananth CV, Neugut AI, Hershman DL, Wright JD. Cost of Care for the Initial Management of Ovarian Cancer. Obstet Gynecol 2017;130:1269-75. [PMID: 29112648 DOI: 10.1097/AOG.0000000000002317] [Cited by in Crossref: 16] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
405 Dougherty BA, Lai Z, Hodgson DR, Orr MCM, Hawryluk M, Sun J, Yelensky R, Spencer SK, Robertson JD, Ho TW, Fielding A, Ledermann JA, Barrett JC. Biological and clinical evidence for somatic mutations in BRCA1 and BRCA2 as predictive markers for olaparib response in high-grade serous ovarian cancers in the maintenance setting. Oncotarget 2017;8:43653-61. [PMID: 28525389 DOI: 10.18632/oncotarget.17613] [Cited by in Crossref: 52] [Cited by in F6Publishing: 44] [Article Influence: 17.3] [Reference Citation Analysis]
406 Xie Y, Jiang Y, Yang XB, Wang AQ, Zheng YC, Wan XS, Sang XT, Wang K, Zhang DD, Xu JJ, Li FG, Zhao HT. Response of BRCA1-mutated gallbladder cancer to olaparib: A case report. World J Gastroenterol 2016;22:10254-9. [PMID: 28028375 DOI: 10.3748/wjg.v22.i46.10254] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
407 Coleman RL, Monk BJ, Sood AK, Herzog TJ. Latest research and treatment of advanced-stage epithelial ovarian cancer. Nat Rev Clin Oncol 2013;10:211-24. [PMID: 23381004 DOI: 10.1038/nrclinonc.2013.5] [Cited by in Crossref: 307] [Cited by in F6Publishing: 286] [Article Influence: 38.4] [Reference Citation Analysis]
408 Gonzalez R, Havrilesky LJ, Myers ER, Secord AA, Dottino JA, Berchuck A, Moss HA. Cost-effectiveness analysis comparing "PARP inhibitors-for-all" to the biomarker-directed use of PARP inhibitor maintenance therapy for newly diagnosed advanced stage ovarian cancer. Gynecol Oncol 2020;159:483-90. [PMID: 32863036 DOI: 10.1016/j.ygyno.2020.08.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
409 Loizzi V, Ranieri G, Laforgia M, Gadaleta CD, Gargano G, Kardhashi A, De Liso M, Naglieri E, Del Vecchio V, Cicinelli E, Cormio G. PARP inhibitors and epithelial ovarian cancer: Molecular mechanisms, clinical development and future prospective. Oncol Lett 2020;20:90. [PMID: 32831909 DOI: 10.3892/ol.2020.11951] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
410 Wilson AJ, Sarfo-Kantanka K, Barrack T, Steck A, Saskowski J, Crispens MA, Khabele D. Panobinostat sensitizes cyclin E high, homologous recombination-proficient ovarian cancer to olaparib. Gynecol Oncol 2016;143:143-51. [PMID: 27444036 DOI: 10.1016/j.ygyno.2016.07.088] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 3.2] [Reference Citation Analysis]
411 Topp MD, Hartley L, Cook M, Heong V, Boehm E, McShane L, Pyman J, McNally O, Ananda S, Harrell M, Etemadmoghadam D, Galletta L, Alsop K, Mitchell G, Fox SB, Kerr JB, Hutt KJ, Kaufmann SH, Australian Ovarian Cancer Study, Swisher EM, Bowtell DD, Wakefield MJ, Scott CL. Molecular correlates of platinum response in human high-grade serous ovarian cancer patient-derived xenografts. Mol Oncol 2014;8:656-68. [PMID: 24560445 DOI: 10.1016/j.molonc.2014.01.008] [Cited by in Crossref: 85] [Cited by in F6Publishing: 74] [Article Influence: 12.1] [Reference Citation Analysis]
412 Cardoso FC, Goncalves S, Mele PG, Liria NC, Sganga L, Diaz Perez I, Podesta EJ, Solano AR. BRCA1 and BRCA2 mutations and clinical interpretation in 398 ovarian cancer patients: comparison with breast cancer variants in a similar population. Hum Genomics 2018;12:39. [PMID: 30103829 DOI: 10.1186/s40246-018-0171-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 3.3] [Reference Citation Analysis]
413 Bajrami I, Frankum JR, Konde A, Miller RE, Rehman FL, Brough R, Campbell J, Sims D, Rafiq R, Hooper S, Chen L, Kozarewa I, Assiotis I, Fenwick K, Natrajan R, Lord CJ, Ashworth A. Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1/2 inhibitor sensitivity. Cancer Res 2014;74:287-97. [PMID: 24240700 DOI: 10.1158/0008-5472.CAN-13-2541] [Cited by in Crossref: 188] [Cited by in F6Publishing: 116] [Article Influence: 23.5] [Reference Citation Analysis]
414 Yan S, Fang J, Chen Y, Xie Y, Zhang S, Zhu X, Fang F. Comprehensive analysis of prognostic gene signatures based on immune infiltration of ovarian cancer. BMC Cancer 2020;20:1205. [PMID: 33287740 DOI: 10.1186/s12885-020-07695-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
415 He ZY, Deng F, Wei XW, Ma CC, Luo M, Zhang P, Sang YX, Liang X, Liu L, Qin HX, Shen YL, Liu T, Liu YT, Wang W, Wen YJ, Zhao X, Zhang XN, Qian ZY, Wei YQ. Ovarian cancer treatment with a tumor-targeting and gene expression-controllable lipoplex. Sci Rep 2016;6:23764. [PMID: 27026065 DOI: 10.1038/srep23764] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.6] [Reference Citation Analysis]
416 Hodgson DR, Dougherty BA, Lai Z, Fielding A, Grinsted L, Spencer S, O'Connor MJ, Ho TW, Robertson JD, Lanchbury JS, Timms KM, Gutin A, Orr M, Jones H, Gilks B, Womack C, Gourley C, Ledermann J, Barrett JC. Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes.Br J Cancer. 2018;119:1401-1409. [PMID: 30353044 DOI: 10.1038/s41416-018-0274-8] [Cited by in Crossref: 67] [Cited by in F6Publishing: 61] [Article Influence: 22.3] [Reference Citation Analysis]
417 Iizuka K, Jin C, Eshima K, Hong MH, Eshima K, Fukushima M. Anticancer activity of the intraperitoneal-delivered DFP-10825, the cationic liposome-conjugated RNAi molecule targeting thymidylate synthase, on peritoneal disseminated ovarian cancer xenograft model. Drug Des Devel Ther 2018;12:673-83. [PMID: 29636601 DOI: 10.2147/DDDT.S156635] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
418 Lee SP, Hsu HC, Tai YJ, Chen YL, Chiang YC, Chen CA, Cheng WF. Bevacizumab Dose Affects the Severity of Adverse Events in Gynecologic Malignancies. Front Pharmacol 2019;10:426. [PMID: 31105567 DOI: 10.3389/fphar.2019.00426] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
419 Hartnett EG, Knight J, Radolec M, Buckanovich RJ, Edwards RP, Vlad AM. Immunotherapy Advances for Epithelial Ovarian Cancer. Cancers (Basel) 2020;12:E3733. [PMID: 33322601 DOI: 10.3390/cancers12123733] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
420 Delgado-Balderas JR, Garza-Rodriguez ML, Gomez-Macias GS, Barboza-Quintana A, Barboza-Quintana O, Cerda-Flores RM, Miranda-Maldonado I, Vazquez-Garcia HM, Valdez-Chapa LD, Antonio-Macedo M, Dean M, Barrera-Saldaña HA. Description of Genetic Variants in BRCA Genes in Mexican Patients with Ovarian Cancer: A First Step towards Implementing Personalized Medicine. Genes (Basel) 2018;9:E349. [PMID: 29997359 DOI: 10.3390/genes9070349] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
421 Matiadis D, Sagnou M. Pyrazoline Hybrids as Promising Anticancer Agents: An Up-to-Date Overview. Int J Mol Sci 2020;21:E5507. [PMID: 32752126 DOI: 10.3390/ijms21155507] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 10.0] [Reference Citation Analysis]
422 Koczkowska M, Zuk M, Gorczynski A, Ratajska M, Lewandowska M, Biernat W, Limon J, Wasag B. Detection of somatic BRCA1/2 mutations in ovarian cancer - next-generation sequencing analysis of 100 cases. Cancer Med 2016;5:1640-6. [PMID: 27167707 DOI: 10.1002/cam4.748] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 4.2] [Reference Citation Analysis]
423 Murai J, Thomas A, Miettinen M, Pommier Y. Schlafen 11 (SLFN11), a restriction factor for replicative stress induced by DNA-targeting anti-cancer therapies. Pharmacol Ther 2019;201:94-102. [PMID: 31128155 DOI: 10.1016/j.pharmthera.2019.05.009] [Cited by in Crossref: 50] [Cited by in F6Publishing: 38] [Article Influence: 25.0] [Reference Citation Analysis]
424 Zhang J, Dai Q, Park D, Deng X. Targeting DNA Replication Stress for Cancer Therapy. Genes (Basel) 2016;7:E51. [PMID: 27548226 DOI: 10.3390/genes7080051] [Cited by in Crossref: 47] [Cited by in F6Publishing: 35] [Article Influence: 9.4] [Reference Citation Analysis]
425 Hu Y, Petit SA, Ficarro SB, Toomire KJ, Xie A, Lim E, Cao SA, Park E, Eck MJ, Scully R, Brown M, Marto JA, Livingston DM. PARP1-driven poly-ADP-ribosylation regulates BRCA1 function in homologous recombination-mediated DNA repair. Cancer Discov 2014;4:1430-47. [PMID: 25252691 DOI: 10.1158/2159-8290.CD-13-0891] [Cited by in Crossref: 67] [Cited by in F6Publishing: 52] [Article Influence: 9.6] [Reference Citation Analysis]
426 Nakagawa Y, Sedukhina AS, Okamoto N, Nagasawa S, Suzuki N, Ohta T, Hattori H, Roche-Molina M, Narváez AJ, Jeyasekharan AD, Bernal JA, Sato K. NF-κB signaling mediates acquired resistance after PARP inhibition. Oncotarget 2015;6:3825-39. [PMID: 25686825 DOI: 10.18632/oncotarget.2868] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 5.4] [Reference Citation Analysis]
427 Gabbasov R, Benrubi ID, O'Brien SW, Krais JJ, Johnson N, Litwin S, Connolly DC. Targeted blockade of HSP90 impairs DNA-damage response proteins and increases the sensitivity of ovarian carcinoma cells to PARP inhibition. Cancer Biol Ther 2019;20:1035-45. [PMID: 30929564 DOI: 10.1080/15384047.2019.1595279] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
428 Sun C, Fang Y, Yin J, Chen J, Ju Z, Zhang D, Chen X, Vellano CP, Jeong KJ, Ng PK, Eterovic AKB, Bhola NH, Lu Y, Westin SN, Grandis JR, Lin SY, Scott KL, Peng G, Brugge J, Mills GB. Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in RAS mutant cancers. Sci Transl Med 2017;9:eaal5148. [PMID: 28566428 DOI: 10.1126/scitranslmed.aal5148] [Cited by in Crossref: 83] [Cited by in F6Publishing: 58] [Article Influence: 27.7] [Reference Citation Analysis]
429 Qian X, Qin J, Pan S, Li X, Pan Y, Ma S. Maintenance Therapy in Ovarian Cancer with Targeted Agents Improves PFS and OS: A Systematic Review and Meta-Analysis. PLoS One 2015;10:e0139026. [PMID: 26402447 DOI: 10.1371/journal.pone.0139026] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
430 Chow YP, Tan LP, Chai SJ, Abdul Aziz N, Choo SW, Lim PV, Pathmanathan R, Mohd Kornain NK, Lum CL, Pua KC, Yap YY, Tan TY, Teo SH, Khoo AS, Patel V. Exome Sequencing Identifies Potentially Druggable Mutations in Nasopharyngeal Carcinoma. Sci Rep 2017;7:42980. [PMID: 28256603 DOI: 10.1038/srep42980] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
431 Bouberhan S, Philp L, Hill S, Al-Alem LF, Rueda B. Exploiting the Prevalence of Homologous Recombination Deficiencies in High-Grade Serous Ovarian Cancer. Cancers (Basel) 2020;12:E1206. [PMID: 32403357 DOI: 10.3390/cancers12051206] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
432 DiSilvestro P, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, Lisyanskaya A, Floquet A, Leary A, Sonke GS, Gourley C, Banerjee S, Oza A, González-Martín A, Aghajanian CA, Bradley WH, Mathews CA, Liu J, Lowe ES, Bloomfield R, Moore KN. Efficacy of Maintenance Olaparib for Patients With Newly Diagnosed Advanced Ovarian Cancer With a BRCA Mutation: Subgroup Analysis Findings From the SOLO1 Trial. J Clin Oncol 2020;38:3528-37. [PMID: 32749942 DOI: 10.1200/JCO.20.00799] [Cited by in Crossref: 10] [Cited by in F6Publishing: 1] [Article Influence: 10.0] [Reference Citation Analysis]
433 Del Conte G, Sessa C, von Moos R, Viganò L, Digena T, Locatelli A, Gallerani E, Fasolo A, Tessari A, Cathomas R, Gianni L. Phase I study of olaparib in combination with liposomal doxorubicin in patients with advanced solid tumours. Br J Cancer 2014;111:651-9. [PMID: 25025963 DOI: 10.1038/bjc.2014.345] [Cited by in Crossref: 66] [Cited by in F6Publishing: 64] [Article Influence: 9.4] [Reference Citation Analysis]
434 Earp MA, Cunningham JM. DNA methylation changes in epithelial ovarian cancer histotypes. Genomics 2015;106:311-21. [PMID: 26363302 DOI: 10.1016/j.ygeno.2015.09.001] [Cited by in Crossref: 34] [Cited by in F6Publishing: 27] [Article Influence: 5.7] [Reference Citation Analysis]
435 Wright S, Porteous M, Stirling D, Lawton J, Young O, Gourley C, Hallowell N. Patients' Views of Treatment-Focused Genetic Testing (TFGT): Some Lessons for the Mainstreaming of BRCA1 and BRCA2 Testing. J Genet Couns 2018. [PMID: 29752676 DOI: 10.1007/s10897-018-0261-5] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
436 LaFargue CJ, Dal Molin GZ, Sood AK, Coleman RL. Exploring and comparing adverse events between PARP inhibitors. Lancet Oncol 2019;20:e15-28. [PMID: 30614472 DOI: 10.1016/S1470-2045(18)30786-1] [Cited by in Crossref: 87] [Cited by in F6Publishing: 38] [Article Influence: 87.0] [Reference Citation Analysis]
437 IJff M, van Bochove GGW, Whitton D, Winiarczyk R, Honhoff C, Rodermond H, Crezee J, Stalpers LJA, Franken NAP, Oei AL. PARP1-Inhibition Sensitizes Cervical Cancer Cell Lines for Chemoradiation and Thermoradiation. Cancers (Basel) 2021;13:2092. [PMID: 33926008 DOI: 10.3390/cancers13092092] [Reference Citation Analysis]
438 Wang S, Yang FJ, Wang X, Zhou Y, Dai B, Han B, Ma HC, Ding YT, Shi XL. PARP-1 promotes tumor recurrence after warm ischemic liver graft transplantation via neutrophil recruitment and polarization. Oncotarget 2017;8:88918-33. [PMID: 29179487 DOI: 10.18632/oncotarget.21493] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
439 Hu K, Wu W, Li Y, Lin L, Chen D, Yan H, Xiao X, Chen H, Chen Z, Zhang Y, Xu S, Guo Y, Koeffler HP, Song E, Yin D. Poly(ADP-ribosyl)ation of BRD7 by PARP1 confers resistance to DNA-damaging chemotherapeutic agents. EMBO Rep 2019;20:e46166. [PMID: 30940648 DOI: 10.15252/embr.201846166] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
440 da Cunha Colombo Bonadio RR, Fogace RN, Miranda VC, Diz MDPE. Homologous recombination deficiency in ovarian cancer: a review of its epidemiology and management. Clinics (Sao Paulo) 2018;73:e450s. [PMID: 30133561 DOI: 10.6061/clinics/2018/e450s] [Cited by in Crossref: 8] [Cited by in F6Publishing: 21] [Article Influence: 2.7] [Reference Citation Analysis]
441 Cont NT, Ferrero A, Peccatori FA, D'Alonzo M, Codacci-Pisanelli G, Colombo N, Biglia N. Medical treatment of early stage and rare histological variants of epithelial ovarian cancer. Ecancermedicalscience 2015;9:584. [PMID: 26557882 DOI: 10.3332/ecancer.2015.584] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
442 Chevrier S, Richard C, Collot T, Mananet H, Arnould L, Boidot R. An Algorithm Combining Patient Performance Status, Second Hit Analysis, PROVEAN and Dann Prediction Tools Could Foretell Sensitization to PARP Inhibitors in Digestive, Skin, Ovarian and Breast Cancers. Cancers (Basel) 2021;13:3113. [PMID: 34206535 DOI: 10.3390/cancers13133113] [Reference Citation Analysis]
443 Meehan RS, Chen AP. New treatment option for ovarian cancer: PARP inhibitors. Gynecol Oncol Res Pract 2016;3:3. [PMID: 27231574 DOI: 10.1186/s40661-016-0024-7] [Cited by in Crossref: 44] [Cited by in F6Publishing: 40] [Article Influence: 8.8] [Reference Citation Analysis]
444 Kuroda T, Hirohashi Y, Torigoe T, Yasuda K, Takahashi A, Asanuma H, Morita R, Mariya T, Asano T, Mizuuchi M, Saito T, Sato N. ALDH1-high ovarian cancer stem-like cells can be isolated from serous and clear cell adenocarcinoma cells, and ALDH1 high expression is associated with poor prognosis. PLoS One 2013;8:e65158. [PMID: 23762304 DOI: 10.1371/journal.pone.0065158] [Cited by in Crossref: 60] [Cited by in F6Publishing: 55] [Article Influence: 7.5] [Reference Citation Analysis]
445 Wang Z, Gao J, Zhou J, Liu H, Xu C. Olaparib induced senescence under P16 or P53 dependent manner in ovarian cancer. J Gynecol Oncol 2019;30:e26. [PMID: 30740957 DOI: 10.3802/jgo.2019.30.e26] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
446 Joo WD, Visintin I, Mor G. Targeted cancer therapy--are the days of systemic chemotherapy numbered? Maturitas 2013;76:308-14. [PMID: 24128673 DOI: 10.1016/j.maturitas.2013.09.008] [Cited by in Crossref: 51] [Cited by in F6Publishing: 38] [Article Influence: 6.4] [Reference Citation Analysis]
447 Chao A, Chang TC, Lapke N, Jung SM, Chi P, Chen CH, Yang LY, Lin CT, Huang HJ, Chou HH, Liou JD, Chen SJ, Wang TH, Lai CH. Prevalence and clinical significance of BRCA1/2 germline and somatic mutations in Taiwanese patients with ovarian cancer. Oncotarget. 2016;7:85529-85541. [PMID: 27907908 DOI: 10.18632/oncotarget.13456] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 8.3] [Reference Citation Analysis]
448 Higuchi T, Flies DB, Marjon NA, Mantia-Smaldone G, Ronner L, Gimotty PA, Adams SF. CTLA-4 Blockade Synergizes Therapeutically with PARP Inhibition in BRCA1-Deficient Ovarian Cancer. Cancer Immunol Res 2015;3:1257-68. [PMID: 26138335 DOI: 10.1158/2326-6066.CIR-15-0044] [Cited by in Crossref: 161] [Cited by in F6Publishing: 93] [Article Influence: 26.8] [Reference Citation Analysis]
449 Osoegawa A, Gills JJ, Kawabata S, Dennis PA. Rapamycin sensitizes cancer cells to growth inhibition by the PARP inhibitor olaparib. Oncotarget 2017;8:87044-53. [PMID: 29152062 DOI: 10.18632/oncotarget.19667] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
450 Dinkic C, Jahn F, Zygmunt M, Schuetz F, Rom J, Sohn C, Fluhr H. PARP inhibition sensitizes endometrial cancer cells to paclitaxel-induced apoptosis. Oncol Lett 2017;13:2847-51. [PMID: 28454476 DOI: 10.3892/ol.2017.5795] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
451 Veskimäe K, Staff S, Grönholm A, Pesu M, Laaksonen M, Nykter M, Isola J, Mäenpää J. Assessment of PARP protein expression in epithelial ovarian cancer by ELISA pharmacodynamic assay and immunohistochemistry. Tumour Biol 2016;37:11991-9. [PMID: 27155850 DOI: 10.1007/s13277-016-5062-6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
452 Kwon M, Jang H, Kim EH, Roh JL. Efficacy of poly (ADP-ribose) polymerase inhibitor olaparib against head and neck cancer cells: Predictions of drug sensitivity based on PAR-p53-NF-κB interactions. Cell Cycle 2016;15:3105-14. [PMID: 27686740 DOI: 10.1080/15384101.2016.1235104] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
453 Mohyuddin GR, Aziz M, Britt A, Wade L, Sun W, Baranda J, Al-Rajabi R, Saeed A, Kasi A. Similar response rates and survival with PARP inhibitors for patients with solid tumors harboring somatic versus Germline BRCA mutations: a Meta-analysis and systematic review. BMC Cancer 2020;20:507. [PMID: 32493233 DOI: 10.1186/s12885-020-06948-5] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 13.0] [Reference Citation Analysis]
454 Garcia TB, Snedeker JC, Baturin D, Gardner L, Fosmire SP, Zhou C, Jordan CT, Venkataraman S, Vibhakar R, Porter CC. A Small-Molecule Inhibitor of WEE1, AZD1775, Synergizes with Olaparib by Impairing Homologous Recombination and Enhancing DNA Damage and Apoptosis in Acute Leukemia. Mol Cancer Ther 2017;16:2058-68. [PMID: 28655785 DOI: 10.1158/1535-7163.MCT-16-0660] [Cited by in Crossref: 34] [Cited by in F6Publishing: 22] [Article Influence: 8.5] [Reference Citation Analysis]
455 Borella F, Ghisoni E, Giannone G, Cosma S, Benedetto C, Valabrega G, Katsaros D. Immune Checkpoint Inhibitors in Epithelial Ovarian Cancer: An Overview on Efficacy and Future Perspectives. Diagnostics (Basel) 2020;10:E146. [PMID: 32156035 DOI: 10.3390/diagnostics10030146] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 18.0] [Reference Citation Analysis]
456 Goff BA. Advanced ovarian cancer: what should be the standard of care? J Gynecol Oncol 2013;24:83-91. [PMID: 23346317 DOI: 10.3802/jgo.2013.24.1.83] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 3.5] [Reference Citation Analysis]
457 Konstantinopoulos PA, Ceccaldi R, Shapiro GI, D'Andrea AD. Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer. Cancer Discov. 2015;5:1137-1154. [PMID: 26463832 DOI: 10.1158/2159-8290.cd-15-0714] [Cited by in Crossref: 347] [Cited by in F6Publishing: 190] [Article Influence: 57.8] [Reference Citation Analysis]
458 Jácome AA, Coutinho AK, Lima EM, Andrade AC, Dos Santos JS. Personalized medicine in gastric cancer: Where are we and where are we going? World J Gastroenterol. 2016;22:1160-1171. [PMID: 26811654 DOI: 10.3748/wjg.v22.i3.1160] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 25] [Article Influence: 6.3] [Reference Citation Analysis]
459 Herzog TJ, Alvarez RD, Secord A, Goff BA, Mannel RS, Monk BJ, Coleman RL. SGO guidance document for clinical trial designs in ovarian cancer: a changing paradigm. Gynecol Oncol 2014;135:3-7. [PMID: 25124162 DOI: 10.1016/j.ygyno.2014.08.004] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]
460 Nizialek E, Antonarakis ES. PARP Inhibitors in Metastatic Prostate Cancer: Evidence to Date. Cancer Manag Res 2020;12:8105-14. [PMID: 32982407 DOI: 10.2147/CMAR.S227033] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 13.0] [Reference Citation Analysis]
461 Lee YJ, Lim MC, Kim BG, Ngoi NY, Choi CH, Park SY, Tan DS, Go Y, Lee JY. A single-arm phase II study of olaparib maintenance with pembrolizumab and bevacizumab in BRCA non-mutated patients with platinum-sensitive recurrent ovarian cancer (OPEB-01). J Gynecol Oncol 2021;32:e31. [PMID: 33559413 DOI: 10.3802/jgo.2021.32.e31] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
462 Turashvili G, Lazaro C, Ying S, Charames G, Wong A, Hamilton K, Yee D, Agro E, Chang M, Pollett A, Lerner-Ellis J. Tumor BRCA Testing in High Grade Serous Carcinoma: Mutation Rates and Optimal Tissue Requirements. Cancers (Basel) 2020;12:E3468. [PMID: 33233347 DOI: 10.3390/cancers12113468] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
463 Kumar R, Paul AM, Rameshwar P, Pillai MR. Epigenetic Dysregulation at the Crossroad of Women's Cancer. Cancers (Basel) 2019;11:E1193. [PMID: 31426393 DOI: 10.3390/cancers11081193] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
464 Westin SN, Herzog TJ, Coleman RL. Investigational agents in development for the treatment of ovarian cancer. Invest New Drugs 2013;31:213-29. [PMID: 22661305 DOI: 10.1007/s10637-012-9837-3] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
465 Sonoda K. Molecular biology of gynecological cancer. Oncol Lett 2016;11:16-22. [PMID: 26834851 DOI: 10.3892/ol.2015.3862] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
466 Barayan R, Ran X, Lok BH. PARP inhibitors for small cell lung cancer and their potential for integration into current treatment approaches. J Thorac Dis 2020;12:6240-52. [PMID: 33209463 DOI: 10.21037/jtd.2020.03.89] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
467 Sachdev E, Tabatabai R, Roy V, Rimel BJ, Mita MM. PARP Inhibition in Cancer: An Update on Clinical Development. Target Oncol 2019;14:657-79. [PMID: 31625002 DOI: 10.1007/s11523-019-00680-2] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 37.0] [Reference Citation Analysis]
468 Ratajska M, Krygier M, Stukan M, Kuźniacka A, Koczkowska M, Dudziak M, Śniadecki M, Dębniak J, Wydra D, Brozek I, Biernat W, Borg A, Limon J, Wasąg B. Mutational analysis of BRCA1/2 in a group of 134 consecutive ovarian cancer patients. Novel and recurrent BRCA1/2 alterations detected by next generation sequencing. J Appl Genet 2015;56:193-8. [PMID: 25366421 DOI: 10.1007/s13353-014-0254-5] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]
469 Caruso D, Papa A, Tomao S, Vici P, Panici PB, Tomao F. Niraparib in ovarian cancer: results to date and clinical potential. Ther Adv Med Oncol 2017;9:579-88. [PMID: 29081841 DOI: 10.1177/1758834017718775] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 4.5] [Reference Citation Analysis]
470 Tung SL, Huang WC, Hsu FC, Yang ZP, Jang TH, Chang JW, Chuang CM, Lai CR, Wang LH. miRNA-34c-5p inhibits amphiregulin-induced ovarian cancer stemness and drug resistance via downregulation of the AREG-EGFR-ERK pathway. Oncogenesis 2017;6:e326. [PMID: 28459431 DOI: 10.1038/oncsis.2017.25] [Cited by in Crossref: 46] [Cited by in F6Publishing: 48] [Article Influence: 11.5] [Reference Citation Analysis]
471 Smith HJ, Straughn JM, Buchsbaum DJ, Arend RC. Epigenetic therapy for the treatment of epithelial ovarian cancer: A clinical review. Gynecol Oncol Rep 2017;20:81-6. [PMID: 28378010 DOI: 10.1016/j.gore.2017.03.007] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 6.5] [Reference Citation Analysis]
472 Cui Y, Brosnan JA, Blackford AL, Sur S, Hruban RH, Kinzler KW, Vogelstein B, Maitra A, Diaz LA Jr, Iacobuzio-Donahue CA, Eshleman JR. Genetically defined subsets of human pancreatic cancer show unique in vitro chemosensitivity. Clin Cancer Res 2012;18:6519-30. [PMID: 22753594 DOI: 10.1158/1078-0432.CCR-12-0827] [Cited by in Crossref: 43] [Cited by in F6Publishing: 28] [Article Influence: 4.8] [Reference Citation Analysis]
473 Muñoz-Galván S, Carnero A. Targeting Cancer Stem Cells to Overcome Therapy Resistance in Ovarian Cancer. Cells 2020;9:E1402. [PMID: 32512891 DOI: 10.3390/cells9061402] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 9.0] [Reference Citation Analysis]
474 Flaum N, Crosbie EJ, Edmondson RJ, Smith MJ, Evans DG. Epithelial ovarian cancer risk: A review of the current genetic landscape. Clin Genet 2020;97:54-63. [PMID: 31099061 DOI: 10.1111/cge.13566] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
475 Morgensztern D, Campo MJ, Dahlberg SE, Doebele RC, Garon E, Gerber DE, Goldberg SB, Hammerman PS, Heist RS, Hensing T, Horn L, Ramalingam SS, Rudin CM, Salgia R, Sequist LV, Shaw AT, Simon GR, Somaiah N, Spigel DR, Wrangle J, Johnson D, Herbst RS, Bunn P, Govindan R. Molecularly targeted therapies in non-small-cell lung cancer annual update 2014. J Thorac Oncol 2015;10:S1-63. [PMID: 25535693 DOI: 10.1097/JTO.0000000000000405] [Cited by in Crossref: 95] [Cited by in F6Publishing: 39] [Article Influence: 15.8] [Reference Citation Analysis]
476 Pishvaian MJ, Biankin AV, Bailey P, Chang DK, Laheru D, Wolfgang CL, Brody JR. BRCA2 secondary mutation-mediated resistance to platinum and PARP inhibitor-based therapy in pancreatic cancer. Br J Cancer 2017;116:1021-6. [PMID: 28291774 DOI: 10.1038/bjc.2017.40] [Cited by in Crossref: 35] [Cited by in F6Publishing: 29] [Article Influence: 8.8] [Reference Citation Analysis]
477 Markman M. Pharmaceutical Management of Ovarian Cancer: Current Status. Drugs 2019;79:1231-9. [PMID: 31267481 DOI: 10.1007/s40265-019-01158-1] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 7.0] [Reference Citation Analysis]
478 Lord CJ, Ashworth A. BRCAness revisited. Nat Rev Cancer 2016;16:110-20. [PMID: 26775620 DOI: 10.1038/nrc.2015.21] [Cited by in Crossref: 576] [Cited by in F6Publishing: 489] [Article Influence: 115.2] [Reference Citation Analysis]
479 Abdullah N, Tamimi Y, Dobretsov S, Balushi NA, Alshekaili J, Al Balushi H, Al Kindi M, Hassan SI, Bahlani SA, Tsang BK, Burney IA. Malformin-A1 (MA1) Sensitizes Chemoresistant Ovarian Cancer Cells to Cisplatin-Induced Apoptosis. Molecules 2021;26:3624. [PMID: 34199287 DOI: 10.3390/molecules26123624] [Reference Citation Analysis]
480 Shang AQ, Wu J, Bi F, Zhang YJ, Xu LR, Li LL, Chen FF, Wang WW, Zhu JJ, Liu YY. Relationship between HER2 and JAK/STAT-SOCS3 signaling pathway and clinicopathological features and prognosis of ovarian cancer. Cancer Biol Ther 2017;18:314-22. [PMID: 28448787 DOI: 10.1080/15384047.2017.1310343] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 5.0] [Reference Citation Analysis]
481 Schuh A, Dreau H, Knight SJL, Ridout K, Mizani T, Vavoulis D, Colling R, Antoniou P, Kvikstad EM, Pentony MM, Hamblin A, Protheroe A, Parton M, Shah KA, Orosz Z, Athanasou N, Hassan B, Flanagan AM, Ahmed A, Winter S, Harris A, Tomlinson I, Popitsch N, Church D, Taylor JC. Clinically actionable mutation profiles in patients with cancer identified by whole-genome sequencing. Cold Spring Harb Mol Case Stud 2018;4:a002279. [PMID: 29610388 DOI: 10.1101/mcs.a002279] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
482 George A, Kaye S, Banerjee S. Delivering widespread BRCA testing and PARP inhibition to patients with ovarian cancer. Nat Rev Clin Oncol 2017;14:284-96. [PMID: 27958297 DOI: 10.1038/nrclinonc.2016.191] [Cited by in Crossref: 90] [Cited by in F6Publishing: 77] [Article Influence: 18.0] [Reference Citation Analysis]
483 Bixel K, Hays JL. Olaparib in the management of ovarian cancer. Pharmgenomics Pers Med 2015;8:127-35. [PMID: 26309417 DOI: 10.2147/PGPM.S62809] [Cited by in Crossref: 10] [Cited by in F6Publishing: 17] [Article Influence: 1.7] [Reference Citation Analysis]
484 Schuller Y, Biegstraaten M, Hollak CEM, Klümpen HJ, Gispen-de Wied CC, Stoyanova-Beninska V. Oncologic orphan drugs approved in the EU - do clinical trial data correspond with real-world effectiveness? Orphanet J Rare Dis 2018;13:214. [PMID: 30486835 DOI: 10.1186/s13023-018-0900-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
485 Quanz M, Hagemann UB, Zitzmann-Kolbe S, Stelte-Ludwig B, Golfier S, Elbi C, Mumberg D, Ziegelbauer K, Schatz CA. Anetumab ravtansine inhibits tumor growth and shows additive effect in combination with targeted agents and chemotherapy in mesothelin-expressing human ovarian cancer models. Oncotarget 2018;9:34103-21. [PMID: 30344925 DOI: 10.18632/oncotarget.26135] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 6.7] [Reference Citation Analysis]
486 Nitecki R, Melamed A, Gockley AA, Floyd J, Krause KJ, Coleman RL, Matulonis UA, Giordano SH, Lu KH, Rauh-Hain JA. Incidence of myelodysplastic syndrome and acute myeloid leukemia in patients receiving poly-ADP ribose polymerase inhibitors for the treatment of solid tumors: A meta-analysis of randomized trials. Gynecol Oncol 2021;161:653-9. [PMID: 33736856 DOI: 10.1016/j.ygyno.2021.03.011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
487 Bai H, Cao D, Yang J, Li M, Zhang Z, Shen K. Genetic and epigenetic heterogeneity of epithelial ovarian cancer and the clinical implications for molecular targeted therapy. J Cell Mol Med 2016;20:581-93. [PMID: 26800494 DOI: 10.1111/jcmm.12771] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 5.4] [Reference Citation Analysis]
488 Li G, Cunin P, Wu D, Diogo D, Yang Y, Okada Y, Plenge RM, Nigrovic PA. The Rheumatoid Arthritis Risk Variant CCR6DNP Regulates CCR6 via PARP-1. PLoS Genet 2016;12:e1006292. [PMID: 27626929 DOI: 10.1371/journal.pgen.1006292] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 3.4] [Reference Citation Analysis]
489 Guy H, Walder L, Fisher M. Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States. Pharmacoeconomics 2019;37:391-405. [PMID: 30478649 DOI: 10.1007/s40273-018-0745-z] [Cited by in Crossref: 17] [Cited by in F6Publishing: 7] [Article Influence: 17.0] [Reference Citation Analysis]
490 Wang Y, Luo W, Wang Y. PARP-1 and its associated nucleases in DNA damage response. DNA Repair (Amst) 2019;81:102651. [PMID: 31302005 DOI: 10.1016/j.dnarep.2019.102651] [Cited by in Crossref: 32] [Cited by in F6Publishing: 24] [Article Influence: 16.0] [Reference Citation Analysis]
491 Pokharel HP, Hacker NF, Andrews L. Improving attendance to genetic counselling services for gynaecological oncology patients. Gynecol Oncol Res Pract 2018;5:2. [PMID: 29344385 DOI: 10.1186/s40661-018-0059-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
492 Dhawan M, Ryan CJ, Ashworth A. DNA Repair Deficiency Is Common in Advanced Prostate Cancer: New Therapeutic Opportunities. Oncologist 2016;21:940-5. [PMID: 27317574 DOI: 10.1634/theoncologist.2016-0135] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]
493 Eccleston A, Bentley A, Dyer M, Strydom A, Vereecken W, George A, Rahman N. A Cost-Effectiveness Evaluation of Germline BRCA1 and BRCA2 Testing in UK Women with Ovarian Cancer. Value Health 2017;20:567-76. [PMID: 28407998 DOI: 10.1016/j.jval.2017.01.004] [Cited by in Crossref: 37] [Cited by in F6Publishing: 21] [Article Influence: 9.3] [Reference Citation Analysis]
494 Pignochino Y, Capozzi F, D'Ambrosio L, Dell'Aglio C, Basiricò M, Canta M, Lorenzato A, Vignolo Lutati F, Aliberti S, Palesandro E, Boccone P, Galizia D, Miano S, Chiabotto G, Napione L, Gammaitoni L, Sangiolo D, Benassi MS, Pasini B, Chiorino G, Aglietta M, Grignani G. PARP1 expression drives the synergistic antitumor activity of trabectedin and PARP1 inhibitors in sarcoma preclinical models. Mol Cancer 2017;16:86. [PMID: 28454547 DOI: 10.1186/s12943-017-0652-5] [Cited by in Crossref: 34] [Cited by in F6Publishing: 28] [Article Influence: 8.5] [Reference Citation Analysis]
495 Pang Y, Lu Y, Caisova V, Liu Y, Bullova P, Huynh TT, Zhou Y, Yu D, Frysak Z, Hartmann I, Taïeb D, Pacak K, Yang C. Targeting NAD+/PARP DNA Repair Pathway as a Novel Therapeutic Approach to SDHB-Mutated Cluster I Pheochromocytoma and Paraganglioma. Clin Cancer Res 2018;24:3423-32. [PMID: 29636359 DOI: 10.1158/1078-0432.CCR-17-3406] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 9.0] [Reference Citation Analysis]
496 Smith HJ, McCaw TR, Londono AI, Katre AA, Meza-Perez S, Yang ES, Forero A, Buchsbaum DJ, Randall TD, Straughn JM Jr, Norian LA, Arend RC. The antitumor effects of entinostat in ovarian cancer require adaptive immunity. Cancer 2018;124:4657-66. [PMID: 30423192 DOI: 10.1002/cncr.31761] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]